


## JOINT INVENTORS

"EXPRESS MAIL" mailing label No.

EL564459107US.

Date of Deposit: March 29, 2001

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231



Richard Zimmermann

## APPLICATION FOR UNITED STATES LETTERS PATENT

# S P E C I F I C A T I O N

---

TO ALL WHOM IT MAY CONCERN:

Be it known that we, Andrew A. Welcher a citizen of the United States of America, residing at 1175 Church Street, Ventura, California 93001 and Frank J. Calzone a citizen of the United States of America, residing at 841 Pine Crest Circle, Westlake Village, California, 91361 have invented new and useful CD20/IgE-Receptor Like molecules and Uses Thereof, of which the following is a specification.

CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF

Related Applications

5           This application is a continuation in part of United States patent application serial no. 09/723,258 filed November 27, 2000 which claims priority from provisional application 60/193,728 filed March 30, 2000 both of which are incorporated herein by reference.

10           Field of the Invention

15           The present invention relates to novel CD20/IgE-receptor like polypeptides and nucleic acid molecules encoding the same. The invention also relates to vectors, host cells, pharmaceutical compositions, selective binding agents and methods for producing CD20/IgE-receptor like polypeptides. Also provided for are methods for the diagnosis, treatment, amelioration, and/or prevention of diseases associated with CD20/IgE-receptor like polypeptides.

20           Background of the Invention

25           Technical advances in the identification, cloning, expression and manipulation of nucleic acid molecules and the deciphering of the human genome have greatly accelerated the discovery of novel therapeutics. Rapid nucleic acid sequencing techniques can now generate sequence information at unprecedented rates and, coupled with computational analyses, allow the assembly of overlapping sequences into partial and entire genomes and the identification of polypeptide-encoding regions. A comparison of a predicted amino acid sequence against a database compilation of known amino acid sequences allows one to determine the extent of homology to previously identified sequences and/or structural landmarks. The cloning and expression of a polypeptide-encoding region of a nucleic

acid molecule provides a polypeptide product for structural and functional analyses. The manipulation of nucleic acid molecules and encoded polypeptides may confer advantageous properties on a product for use as a therapeutic.

5 In spite of the significant technical advances in genome research over the past decade, the potential for the development of novel therapeutics based on the human genome is still largely unrealized. Many genes encoding potentially beneficial polypeptide therapeutics, or those encoding  
10 polypeptides, which may act as "targets" for therapeutic molecules, have still not been identified.

Accordingly, it is an object of the invention to identify novel polypeptides and nucleic acid molecules encoding the same, which have diagnostic or therapeutic benefit.

15 Summary of the Invention

The present invention relates to novel CD20/IgE-receptor like nucleic acid molecules and encoded polypeptides.

The invention provides for an isolated nucleic acid  
20 molecule comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence as set forth in either SEQ ID NO: 1 OR SEQ ID NO: 3;

(b) a nucleotide sequence encoding the polypeptide as  
25 set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(c) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of (a) or (b), wherein the encoded polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID  
30 NO: 4; and

(d) a nucleotide sequence complementary to any of (a)-  
(c).

The invention also provides for an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

5 (a) a nucleotide sequence encoding a polypeptide that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO:  
10 2 or SEQ ID NO: 4 as determined using a computer program such as GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit or the Smith-Waterman algorithm;

(b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in  
15 either SEQ ID NO: 1 OR SEQ ID NO: 3, wherein the encoded polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(c) a nucleotide sequence of either SEQ ID NO: 1 OR SEQ ID NO: 3, (a), or (b) encoding a polypeptide fragment of at  
20 least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(d) a nucleotide sequence of either SEQ ID NO: 1 OR SEQ ID NO: 3, or (a)-(d) comprising a fragment of at least about  
25 16 nucleotides;

(e) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(d), wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO:  
30 4; and

(f) a nucleotide sequence complementary to any of (a)-(e).

The invention further provides for an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(b) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(c) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(d) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 which has a C- and/or N- terminal truncation, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(e) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(f) a nucleotide sequence of (a)-(e) comprising a fragment of at least about 16 nucleotides;

(g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f), wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO:

5 4; and

(h) a nucleotide sequence complementary to any of (a)-(e).

The invention also provides for an isolated polypeptide comprising the amino acid sequence selected from the group  
10 consisting of:

(a) an amino acid sequence for an ortholog of either SEQ ID NO: 2 or SEQ ID NO: 4, wherein the encoded polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

15 (b) an amino acid sequence that is at least about 70, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 as determined  
20 using a computer program such as GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit or the Smith-Waterman algorithm;

(c) a fragment of the amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 comprising at least about 25 amino acid residues, wherein the polypeptide has an  
25 activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

(d) an amino acid sequence for an allelic variant or splice variant of either the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, or at least one of  
30 (a)-(b) wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

The invention further provides for an isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

5 (a) the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

10 (b) the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

15 (c) the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;

20 (d) the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 which has a C- and/or N-terminal truncation, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4; and

25 (e) the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

30 Also provided are fusion polypeptides comprising the amino acid sequences of (a)-(e) above.

The present invention also provides for an expression vector comprising the isolated nucleic acid molecules as set forth herein, recombinant host cells comprising recombinant

nucleic acid molecules as set forth herein, and a method of producing a CD20/IgE-receptor like polypeptide comprising culturing the host cells and optionally isolating the polypeptide so produced.

5 A transgenic non-human animal comprising a nucleic acid molecule encoding a CD20/IgE-receptor like polypeptide is also encompassed by the invention. The CD20/IgE-receptor like nucleic acid molecules are introduced into the animal in a manner that allows expression and increased levels of the  
10 CD20/IgE-receptor like polypeptide, which may include increased circulating levels. The transgenic non-human animal is preferably a mammal.

Also provided are derivatives of the CD20/IgE-receptor like polypeptides of the present invention.

15 Analogs of the CD20/IgE-receptor like polypeptides are provided for in the present invention which result from conservative and/or non-conservative amino acids substitutions of the CD20/IgE-receptor like polypeptides of SEQ ID NO: 2 or 4. Such analogs include an CD20/IgE-receptor like polypeptide  
20 wherein, for example the amino acid at position 86 of SEQ ID NO: 2 or 4 is glycine, proline or alanine, the amino acid at position 95 of SEQ ID NO: 2 or 4 is phenylalanine, leucine, valine, isoleucine, alanine or tyrosine, the amino acid at position 121 of SEQ ID NO: 2 or 4 is asparagine or glutamine,  
25 the amino acid at position 128 of SEQ ID NO: 2 or 4 is alanine, valine, isoleucine, or leucine, the amino acid at position 103 of SEQ ID NO: 2 or 4 is isoleucine, leucine, valine, methionine, alanine, phenylalanine or norleucine.

Additionally provided are selective binding agents such  
30 as antibodies and peptides capable of specifically binding the CD20/IgE-receptor like polypeptides of the invention. Such antibodies, polypeptides, peptides and small molecules may be agonistic or antagonistic.



Additionally provided are selective binding agents such as antibodies and peptides capable of specifically binding the CD20/IgE-receptor like polypeptides of the invention. Such antibodies and peptides may be agonistic or antagonistic.

5       Pharmaceutical compositions comprising the nucleotides, polypeptides, or selective binding agents of the present invention and one or more pharmaceutically acceptable formulation agents are also encompassed by the invention. The pharmaceutical compositions are used to provide  
10 therapeutically effective amounts of the nucleotides or polypeptides of the present invention. The invention is also directed to methods of using the polypeptides, nucleic acid molecules, and selective binding agents.

15       The CD20/IgE-receptor like polypeptides and nucleic acid molecules of the present invention may be used to treat, prevent, ameliorate, and/or detect diseases and disorders, including those recited herein.

20       The invention encompasses diagnosing a pathological condition or the susceptibility to a pathological condition in a subject caused by or resulting from abnormal (i.e. increased or decreased) levels of CD20/IgE-receptor like polypeptide comprising determining the presence or amount of expression of the CD20/IgE-receptor like polypeptide in a sample and comprising the level of said polypeptide in a biological,  
25 tissue or cellular sample from either normal subjects or the subject at an earlier time, wherein susceptibility to a pathological condition is based on the presence or amount of expression of the polypeptide.

30       Methods of regulating expression and modulating (i.e., increasing or decreasing) levels of a CD20/IgE-receptor like polypeptide are also encompassed by the invention. One method comprises administering to an animal a nucleic acid molecule encoding a CD20/IgE-receptor like polypeptide. In another method, a nucleic acid molecule comprising elements that

regulate or modulate the expression of a CD20/IgE-receptor like polypeptide may be administered. Examples of these methods include gene therapy, cell therapy, and anti-sense therapy as further described herein.

5       The CD20/IgE-receptor like polypeptide can be used for identifying ligands thereof. Various forms of "expression cloning" have been used for cloning ligands for receptors. See e.g., Davis et al., *Cell*, 87:1161-1169 (1996). These and other CD20/IgE-receptor like ligand cloning experiments are  
10       described in greater detail herein. Isolation of the CD20/IgE-receptor like ligand(s) allows for the identification or development of novel agonists and/or antagonists of the CD20/IgE-receptor like signaling pathway.

15       The invention further encompasses methods for determine the presence of CD20/IgE-receptor like nucleic acids in a biological, tissue or cellular sample . These methods comprise the steps of providing a biological sample suspected of containing CD20/IgE-receptor like nucleic acids; contacting the biological sample with a diagnostic reagent of the present  
20       invention under conditions wherein the diagnostic reagent will hybridize with CD20/IgE-receptor like nucleic acids contained in said biological sample; detecting hybridization between nucleic acid in the biological sample and the diagnostic reagent; and comparing the level of hybridization between the  
25       biological sample and diagnostic reagent with the level of hybridization between a known concentration of CD20/IgE-receptor like nucleic acid and the diagnostic reagent. The polynucleotide detected in these methods may be an CD20/IgE-receptor like DNA or and CD20/IgE-receptor like RNA.

30       The present invention provides for methods of identifying antagonists or agonists of CD20/IgE-receptor like biological activity comprising contacting a small molecule compound with CD20/IgE-receptor like polypeptides and measuring CD20/IgE-receptor like biological activity in the presence and absence

of these small molecules. These small molecules can be a naturally occurring medicinal compound or derived from combinational chemical libraries. In certain embodiments, an CD20/IgE-receptor like polypeptide agonist or antagonist may  
5 be a protein, peptide, carbohydrate, lipid, or small molecule which interacts with a CD20/IgE-receptor like polypeptide to regulate its activity.

Agonists and antagonists include, but are not limited to, ligands to the CD20/IgE-receptor like polypeptides, soluble  
10 CD20/IgE-receptor like polypeptides, anti-CD20/IgE-receptor like selective binding agents (such as antibodies and derivatives thereof), small molecules, peptides and derivatives thereof capable of binding CD-220/IgE-receptor polypeptide or antisense oligonucleotides, any of which can be  
15 used for treating one or more disease or disorder, including those disclosed herein.

The invention also provides for a device which comprises a membrane suitable for implantation in a patient; and cells encapsulated within said membrane, wherein said cells secrete  
20 an CD20/IgE-receptor like polypeptide of the invention wherein the membrane is permeable to the protein product and impermeable to materials detrimental to said cells. The invention further provides for a device which comprises a membrane suitable for implantation and the CD20/IgE-receptor  
25 like polypeptide encapsulated in a membrane that is permeable to the polypeptide.

The invention provides for a CD20/IgE-receptor like polynucleotide attached to a solid support. The invention also provides for an array of polynucleotides comprising at  
30 least one CD20/IgE receptor-like polynucleotide.

#### **Brief Description of the Figures**

Figure 1 depicts the nucleic acid sequence (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) of a first human

CD20/IgE-receptor like polypeptide (termed "agp-96614-a1").

Figure 2 depicts the nucleic acid sequence (SEQ ID NO: 3) and amino acid sequence (SEQ ID NO: 4) of a second human CD20/IgE-receptor like polypeptide (termed "agp-69406-a1").

5        Figure 3 (SEQ ID NO: 5) depicts amino acid homology of the present human CD20/IgE-receptor like polypeptides (Agp-69406-a1 and Agp-96614-a1) and known CD20/IgE-receptor like receptor family members. In Figure 3, Agp-69406-a1 and Agp-96614-a1 are abbreviated "69406" and "96614" respectively.

10

### Detailed Description of the Invention

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All references cited in this application are expressly incorporated by reference herein.

### Definitions

20        The terms "CD20/IgE-receptor like gene" or "CD20/IgE-receptor like nucleic acid molecule" or "polynucleotide" refers to a nucleic acid molecule comprising or consisting of a nucleotide sequence as set forth in either SEQ ID NO: 1 OR SEQ ID NO: 3, a nucleotide sequence encoding the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, a nucleotide sequence of the DNA insert in ATCC deposit nos. 25        PTA-1739 and PTA-1740 (deposited with the American Tissue Culture Collection (ATCC) 10801 University Blvd. Manassas VA on April 19, 2000) and nucleic acid molecules as defined herein.

30        The term "CD20/IgE-receptor like polypeptide" refers to a polypeptide comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4, and related polypeptides. Related polypeptides include: CD20/IgE-receptor like polypeptide allelic variants, CD20/IgE-receptor like polypeptide

orthologs, CD20/IgE-receptor like polypeptide splice variants, CD20/IgE-receptor like polypeptide variants and CD20/IgE-receptor like polypeptide derivatives. CD20/IgE-receptor like polypeptides may be mature polypeptides, as defined herein, and may or may not have an amino terminal methionine residue, depending on the method by which they are prepared.

The term "CD20/IgE-receptor like polypeptide allelic variant" refers to one of several possible naturally occurring alternate forms of a gene occupying a given locus on a chromosome of an organism or a population of organisms.

The term "CD20/IgE-receptor like polypeptide derivatives" refers to the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, CD20/IgE-receptor like polypeptide allelic variants, CD20/IgE-receptor like polypeptide orthologs, CD20/IgE-receptor like polypeptide splice variants, or CD20/IgE-receptor like polypeptide variants, as defined herein, that have been chemically modified.

The term "CD20/IgE-receptor like polypeptide fragment" refers to a polypeptide that comprises a truncation at the amino terminus (with or without a leader sequence) and/or a truncation at the carboxy terminus of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, CD20/IgE-receptor like polypeptide allelic variants, CD20/IgE-receptor like polypeptide orthologs, CD20/IgE-receptor like polypeptide splice variants and/or a CD20/IgE-receptor like polypeptide variant having one or more amino acid additions or substitutions or internal deletions (wherein the resulting polypeptide is at least 6 amino acids or more in length) as compared to the CD20/IgE-receptor like polypeptide amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4. CD20/IgE-receptor like polypeptide fragments may result from alternative RNA splicing or from *in vivo* protease activity. For transmembrane or membrane-bound forms of a CD20/IgE-

receptor like polypeptide, preferred fragments include soluble forms such as those lacking a transmembrane or membrane-binding domain. In preferred embodiments, truncations comprise about 10 amino acids, or about 20 amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or more than about 100 amino acids. The polypeptide fragments so produced will comprise about 25 contiguous amino acids, or about 50 amino acids, or about 75 amino acids, or about 100 amino acids, or about 150 amino acids, or about 200 amino acids. Such CD20/IgE-receptor like polypeptide fragments may optionally comprise an amino terminal methionine residue. It will be appreciated that such fragments can be used, for example, to generate antibodies to CD20/IgE-receptor like polypeptides.

The term "CD20/IgE-receptor like fusion polypeptide" refers to a fusion of one or more amino acids (such as a heterologous peptide or polypeptide) at the amino or carboxy terminus of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, CD20/IgE-receptor like polypeptide allelic variants, CD20/IgE-receptor like polypeptide orthologs, CD20/IgE-receptor like polypeptide splice variants, or CD20/IgE-receptor like polypeptide variants having one or more amino acid deletions, substitutions or internal additions as compared to the CD20/IgE-receptor like polypeptide amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

The term "CD20/IgE-receptor like polypeptide ortholog" refers to a polypeptide from another species that corresponds to CD20/IgE-receptor like polypeptide amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4. For example, mouse and human CD20/IgE-receptor like polypeptides are considered orthologs of each other.

The term "CD20/IgE-receptor like polypeptide splice variant" refers to a nucleic acid molecule, usually RNA, which

is generated by alternative processing of intron sequences in an RNA transcript of CD20/IgE-receptor like polypeptide amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

5       The term "CD20/IgE-receptor like polypeptide variants" refers to CD20/IgE-receptor like polypeptides comprising amino acid sequences having one or more amino acid sequence substitutions, deletions (such as internal deletions and/or CD20/IgE-receptor like polypeptide fragments), and/or  
10 additions (such as internal additions and/or CD20/IgE-receptor like fusion polypeptides) as compared to the CD20/IgE-receptor like polypeptide amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 (with or without a leader sequence). Variants may be naturally occurring (e.g., CD20/IgE-receptor  
15 like polypeptide allelic variants, CD20/IgE-receptor like polypeptide orthologs and CD20/IgE-receptor like polypeptide splice variants) or artificially constructed. Such CD20/IgE-receptor like polypeptide variants may be prepared from the corresponding nucleic acid molecules having a DNA sequence  
20 that varies accordingly from the DNA sequence as set forth in either SEQ ID NO: 1 OR SEQ ID NO: 3. In preferred embodiments, the variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from 1 to 15, or from 1 to 20, or from 1 to 25, or from 1 to 50, or from 1 to 75, or from 1 to 100, or  
25 more than 100 amino acid substitutions, insertions, additions and/or deletions, wherein the substitutions may be conservative, or non-conservative, or any combination thereof.

30       The term "antigen" refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antibody, and additionally capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen. An antigen may have one or more epitopes. The specific binding reaction referred to above is meant to indicate that the antigen will react, in a highly

selective manner, with its corresponding antibody and not with the multitude of other antibodies which can be evoked by other antigens.

5 The term "biologically active CD20/IgE-receptor like polypeptides" refers to CD20/IgE-receptor like polypeptides having at least one activity characteristic of the polypeptide comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4. In general, CD20/IgE-receptor like polypeptides, fragments, variants, and derivatives thereof, 10 will have at least one activity characteristic of a CD20/IgE-receptor like polypeptide such as depicted in SEQ ID NO: 2 or SEQ ID NO: 4. In addition, a CD20/IgE-receptor like polypeptide may be active as an immunogen, that is, the polypeptide contains at least one epitope to which antibodies 15 may be raised.

The terms "effective amount" and "therapeutically effective amount" each refer to the amount of a CD20/IgE-receptor like polypeptide or CD20/IgE-receptor like nucleic acid molecule used to support an observable level of one or 20 more biological activities of the CD20/IgE-receptor like polypeptides as set forth herein.

The term "expression vector" refers to a vector which is suitable for use in a host cell and contains nucleic acid sequences which direct and/or control the expression of 25 heterologous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present.

The term "host cell" is used to refer to a cell which has been transformed, or is capable of being transformed with a 30 nucleic acid sequence and then of expressing a selected gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the



selected gene is present.

The term "identity" as known in the art, refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between nucleic acid molecules or polypeptides, as the case may be, as determined by the match between strings of two or more nucleotide or two or more amino acid sequences. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., "algorithms").

The term "similarity" is a related concept, but in contrast to "identity", refers to a measure of similarity which includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, 10/20 identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If in the same example, there are 5 more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (15/20). Therefore, in cases where there are conservative substitutions, the degree of similarity between two polypeptides will be higher than the percent identity between those two polypeptides.

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates or other materials with which it is naturally found when total DNA is isolated from the source cells, (2) is not linked to all or a portion of a polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3)

is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from at least one contaminating nucleic acid molecule with which it is naturally associated. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecule(s) or other contaminants that are found in its natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic or research use.

The term "isolated polypeptide" refers to a polypeptide of the present invention that (1) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates or other materials with which it is naturally found when isolated from the cell source, (2) is not linked (by covalent or noncovalent interaction) to all or a portion of a polypeptide to which the "isolated polypeptide" is linked in nature, (3) is operably linked (by covalent or noncovalent interaction) to a polypeptide with which it is not linked in nature, or (4) does not occur in nature. Preferably, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment. Preferably, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment which would interfere with its therapeutic, diagnostic, prophylactic or research use.

The term "mature CD20/IgE-receptor like polypeptide" refers to a CD20/IgE-receptor like polypeptide lacking a leader sequence. A mature CD20/IgE-receptor like polypeptide may also include other modifications such as proteolytic processing of the amino terminus (with or without a leader sequence) and/or the carboxy terminus, cleavage of a smaller

polypeptide from a larger precursor, N-linked and/or O-linked glycosylation, and the like.

The term "nucleic acid sequence" or "nucleic acid molecule" refers to a DNA or RNA sequence. The term encompasses molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylaminomethyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyamino-methyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonyl-methyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.

The term "naturally occurring" or "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to materials which are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" as used herein refers to a material that is not found in nature or that has been structurally modified or synthesized by man.

The term "operably linked" is used herein to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to

perform their usual function. Thus, a flanking sequence operably linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of the CD20/IgE-receptor like polypeptide, CD20/IgE-receptor like nucleic acid molecule or CD20/IgE-receptor like selective binding agent as a pharmaceutical composition.

The term "selective binding agent" refers to a molecule or molecules having specificity for a CD20/IgE-receptor like polypeptide. Selective binding agents include antibodies, such as polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, CDR-grafted antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound forms, as well as fragments, regions, or derivatives thereof which are provided by known techniques, including, but not limited to enzymatic cleavage, peptide synthesis or recombinant techniques. The anti-CD20/IgE-receptor like selective binding agents of the present invention are capable, for example, of binding portions of CD20/IgE like receptors.

As used herein, the terms, "specific" and "specificity" refer to the ability of the selective binding agents to bind to human CD20/IgE-receptor like polypeptides and not to bind to human non-CD20/IgE-receptor like polypeptides. It will be appreciated, however, that the selective binding agents may also bind orthologs of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, that is, interspecies versions thereof, such as mouse and rat polypeptides.

CD20/IgE-receptor like polypeptides, fragments, variants, and derivatives may be used to prepare CD20/IgE-receptor like selective binding agents using methods known in the art. Thus, antibodies and antibody fragments that bind CD20/IgE-receptor like polypeptides are within the scope of the present invention. Antibody fragments include those portions of the antibody which bind to an epitope on the CD20/IgE-receptor like polypeptide. Examples of such fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions. These antibodies may be, for example, polyclonal monospecific polyclonal, monoclonal, recombinant, chimeric, humanized, human, single chain, and/or bispecific.

The term "transduction" is used to refer to the transfer of genes from one bacterium to another, usually by a phage. "Transduction" also refers to the acquisition and transfer of eukaryotic cellular sequences by retroviruses.

The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, for

example, Graham et al., *Virology*, 52:456 (1973); Sambrook et al., *Molecular Cloning, a laboratory Manual*, Cold Spring Harbor Laboratories (New York, 1989); Davis et al., *Basic Methods in Molecular Biology*, Elsevier, 1986; and Chu et al.,  
5 *Gene*, 13:197 (1981). Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new  
10 DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, may be maintained transiently as an  
15 episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

The term "vector" is used to refer to any molecule (e.g.,  
20 nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.

#### Relatedness of Nucleic Acid Molecules and/or Polypeptides

It is understood that related nucleic acid molecules  
25 include allelic or splice variants of the nucleic acid molecule of either SEQ ID NO: 1 or SEQ ID NO: 3, and include sequences which are complementary to any of the above nucleotide sequences. Related nucleic acid molecules also include a nucleotide sequence encoding a polypeptide  
30 comprising or consisting essentially of a substitution, modification, addition and/or a deletion of one or more amino acid residues compared to the polypeptide in either SEQ ID NO: 2 or SEQ ID NO: 4.

Fragments include molecules which encode a polypeptide of at least about 25 amino acid residues, or about 50, or about 75, or about 100, or greater than about 100 amino acid residues of the polypeptide of either SEQ ID NO: 2 or SEQ ID NO: 4.

In addition, related CD20/IgE-receptor like nucleic acid molecules include those molecules which comprise nucleotide sequences which hybridize under moderately or highly stringent conditions as defined herein with the fully complementary sequence of the nucleic acid molecule of either SEQ ID NO: 1 OR SEQ ID NO: 3, or of a molecule encoding a polypeptide, which polypeptide comprises the amino acid sequence as shown in either SEQ ID NO: 2 or SEQ ID NO: 4, or of a nucleic acid fragment as defined herein, or of a nucleic acid fragment encoding a polypeptide as defined herein. Hybridization probes may be prepared using the CD20/IgE-receptor like sequences provided herein to screen cDNA, genomic or synthetic DNA libraries for related sequences. Regions of the DNA and/or amino acid sequence of CD20/IgE-receptor like polypeptide that exhibit significant identity to known sequences are readily determined using sequence alignment algorithms as described herein and those regions may be used to design probes for screening.

The term "highly stringent conditions" refers to those conditions that are designed to permit hybridization of DNA strands whose sequences are highly complementary, and to exclude hybridization of significantly mismatched DNAs. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of "highly stringent conditions" for hybridization and washing are 0.015M sodium chloride, 0.0015M sodium citrate at 65-68°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. See Sambrook, Fritsch & Maniatis, Molecular Cloning: A

Laboratory Manual, 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989); Anderson *et al.*, Nucleic Acid Hybridisation: a practical approach, Ch. 4, IRL Press Limited (Oxford, England).

5        More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may also be used, however, the rate of hybridization will be affected. Other agents may be included in the hybridization and washing buffers for the purpose of reducing  
10 non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate (NaDodSO<sub>4</sub> or SDS), ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate,  
15 although other suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic  
20 strength conditions, the rate of hybridization is nearly independent of pH. See Anderson *et al.*, Nucleic Acid Hybridisation: a Practical Approach, Ch. 4, IRL Press Limited (Oxford, England).

Factors affecting the stability of a DNA duplex include  
25 base composition, length, and degree of base pair mismatch. Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids. The melting temperature of a perfectly matched DNA duplex can be estimated  
30 by the following equation:

$$T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log[\text{Na}^+]) + 0.41(\% \text{G+C}) - 600/N - 0.72(\% \text{formamide})$$

where N is the length of the duplex formed, [Na<sup>+</sup>] is the molar concentration of the sodium ion in the hybridization or



washing solution, %G+C is the percentage of (guanine+cytosine) bases in the hybrid. For imperfectly matched hybrids, the melting temperature is reduced by approximately 1°C for each 1% mismatch.

5       The term "moderately stringent conditions" refers to conditions under which a DNA duplex with a greater degree of base pair mismatching than could occur under "highly stringent conditions" is able to form. Examples of typical "moderately stringent conditions" are 0.015M sodium chloride, 0.0015M  
10   sodium citrate at 50-65°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 20% formamide at 37-50°C. By way of example, a "moderately stringent" condition of 50°C in 0.015 M sodium ion will allow about a 21% mismatch.

15       It will be appreciated by those skilled in the art that there is no absolute distinction between "highly" and "moderately" stringent conditions. For example, at 0.015M sodium ion (no formamide), the melting temperature of perfectly matched long DNA is about 71°C. With a wash at 65°C (at the same ionic strength), this would allow for  
20   approximately a 6% mismatch. To capture more distantly related sequences, one skilled in the art can simply lower the temperature or raise the ionic strength.

A good estimate of the melting temperature in 1M NaCl\* for oligonucleotide probes up to about 20nt is given by:

25        $T_m = 2^{\circ}\text{C per A-T base pair} + 4^{\circ}\text{C per G-C base pair}$

\*The sodium ion concentration in 6X salt sodium citrate (SSC) is 1M. See Suggs et al., Developmental Biology Using Purified Genes, p. 683, Brown and Fox (eds.) (1981).

30       High stringency washing conditions for oligonucleotides are usually at a temperature of 0-5°C below the  $T_m$  of the oligonucleotide in 6X SSC, 0.1% SDS.

In another embodiment, related nucleic acid molecules comprise or consist of a nucleotide sequence that is about 70 percent identical to the nucleotide sequence as shown in either SEQ ID NO: 1 OR SEQ ID NO: 3, or comprise or consist essentially of a nucleotide sequence encoding a polypeptide that is about 70 percent identical to the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4. In preferred embodiments, the nucleotide sequences are about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the nucleotide sequence as shown in either SEQ ID NO: 1 or SEQ ID NO: 3, or the nucleotide sequences encode a polypeptide that is about 75 percent, or about 80 percent, or about 85 percent, or about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the polypeptide sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

Differences in the nucleic acid sequence may result in conservative and/or non-conservative modifications of the amino acid sequence relative to the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4.

Conservative modifications to the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4 (and the corresponding modifications to the encoding nucleotides) will produce CD20/IgE-receptor like polypeptides having functional and chemical characteristics similar to those of naturally occurring CD20/IgE-receptor like polypeptide. In contrast, substantial modifications in the functional and/or chemical characteristics of CD20/IgE-receptor like polypeptides may be accomplished by selecting substitutions in the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4 that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or

hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

For example, a "conservative amino acid substitution" may involve a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for "alanine scanning mutagenesis."

Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties. It will be appreciated by those of skill in the art that nucleic acid and polypeptide molecules described herein may be chemically synthesized as well as produced by recombinant means.

Naturally occurring residues may be divided into classes based on common side chain properties:

- 1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
- 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- 3) acidic: Asp, Glu;
- 4) basic: His, Lys, Arg;
- 5) residues that influence chain orientation: Gly, Pro; and
- 6) aromatic: Trp, Tyr, Phe.

For example, non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the human CD20/IgE-receptor like polypeptide that are homologous with non-human CD20/IgE-

receptor like polypeptide orthologs, or into the non-homologous regions of the molecule.

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art. Kyte et al., *J. Mol. Biol.*, 157:105-131 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functionally equivalent protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. The greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.

The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4);  
5 proline (-0.5  $\pm$  1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). In making changes based upon similar hydrophilicity values, the substitution of amino acids whose  
10 hydrophilicity values are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to  
15 as "epitopic core regions."

Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important  
20 residues of the CD20/IgE-receptor like polypeptide, or to increase or decrease the affinity of the CD20/IgE-receptor like polypeptides described herein.

Exemplary amino acid substitutions are set forth in Table I.

25

30

**Table I**  
**Amino Acid Substitutions**

Original Residues	Exemplary Substitutions	Preferred Substitutions
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln	Gln
Asp	Glu	Glu
Cys	Ser, Ala	Ser
Gln	Asn	Asn
Glu	Asp	Asp
Gly	Pro, Ala	Ala
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleucine	Leu
Leu	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, 1,4 Diamino-butyric Acid, Gln, Asn	Arg
Met	Leu, Phe, Ile	Leu
Phe	Leu, Val, Ile, Ala, Tyr	Leu
Pro	Ala	Gly
Ser	Thr, Ala, Cys	Thr
Thr	Ser	Ser
Trp	Tyr, Phe	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

A skilled artisan will be able to determine suitable variants of the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 using well known techniques. For example,

one may predict suitable areas of the molecule that may be changed without destroying biological activity. Also, one skilled in the art will realize that even areas that may be important for biological activity or for structure may be  
5 subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

For example, when similar polypeptides with similar activities from the same species or from other species are  
10 known, one skilled in the art may compare the amino acid sequence of a CD20/IgE-receptor like polypeptide to such similar polypeptides. With such a comparison, one can identify residues and portions of the molecules that are conserved among similar polypeptides. It will be appreciated  
15 that changes in areas of a CD20/IgE-receptor like polypeptide that are not conserved relative to such similar polypeptides would be less likely to adversely affect the biological activity and/or structure of the CD20/IgE-receptor like polypeptide. One skilled in the art would also know that,  
20 even in relatively conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (conservative amino acid residue substitutions). Therefore, even areas that may be important for biological activity or for structure may be  
25 subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

For predicting suitable areas of the molecule that may be changed without destroying activity, one skilled in the art  
30 may target areas not believed to be important for activity. For example, when similar polypeptides with similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of

CD20/IgE-receptor like polypeptide to such similar polypeptides. After making such a comparison, one skilled in the art can determine residues and portions of the molecules that are conserved among similar polypeptides. One skilled in  
5 the art would know that changes in areas of the CD20/IgE-receptor like molecule that are not conserved would be less likely to adversely affect the biological activity and/or structure of a CD20/IgE-receptor like polypeptide. One skilled in the art would also know that, even in relatively  
10 conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (conservative amino acid residue substitutions).

Additionally, one skilled in the art can review structure-function studies identifying residues in similar  
15 polypeptides that are important for activity or structure. In view of such a comparison, one can predict the importance of amino acid residues in a CD20/IgE-receptor like polypeptide that correspond to amino acid residues that are important for activity or structure in similar polypeptides. One skilled in  
20 the art may opt for chemically similar amino acid substitutions for such predicted important amino acid residues of CD20/IgE-receptor like polypeptides.

One skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to  
25 that structure in similar polypeptides. In view of that information, one skilled in the art may predict the alignment of amino acid residues of a CD20/IgE-receptor like polypeptide with respect to its three dimensional structure. One skilled in the art may choose not to make radical changes to amino  
30 acid residues predicted to be on the surface of the protein, since such residues may be involved in important interactions with other molecules. Moreover, one skilled in the art may generate test variants containing a single amino acid substitution at each desired amino acid residue. The variants



can then be screened using activity assays known to those skilled in the art. Such variants could be used to gather information about suitable variants. For example, if one discovered that a change to a particular amino acid residue resulted in destroyed, undesirably reduced, or unsuitable activity, variants with such a change would be avoided. In other words, based on information gathered from such routine experiments, one skilled in the art can readily determine the amino acids where further substitutions should be avoided either alone or in combination with other mutations.

A number of scientific publications have been devoted to the prediction of secondary structure. See Moulton J., *Curr. Opin. in Biotech.*, 7(4):422-427 (1996), Chou et al., *Biochemistry*, 13(2):222-245 (1974); Chou et al., *Biochemistry*, 113(2):211-222 (1974); Chou et al., *Adv. Enzymol. Relat. Areas Mol. Biol.*, 47:45-148 (1978); Chou et al., *Ann. Rev. Biochem.*, 47:251-276 and Chou et al., *Biophys. J.*, 26:367-384 (1979). Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based on the Jameson-Wolfe analysis (Jameson et al., *Comput. Appl. Biosci.*, 4(1):181-186 (1988) and Wolfe et al., *Comput. Appl. Biosci.* 4(1): 187-191 (1988), the program PepPlot® (Brutlag et al. *CABS* 6:237-245 (1990), and Weinberger et al., *Science* 228:740-742 (1985), and other new programs for protein tertiary structure prediction (Fetrow et al., *Biotechnology*, 11:479-483 (1993).

Moreover, computer programs are currently available to assist in predicting secondary structure. One method of predicting secondary structure is based upon homology modeling. For example, two polypeptides or proteins which have a sequence identity of greater than 30%, or similarity greater than 40% often have similar structural topologies. The recent growth of the protein structural data base (PDB)

has provided enhanced predictability of secondary structure, including the potential number of folds within a polypeptide's or protein's structure. See Holm et al., *Nucl. Acid. Res.*, 27(1):244-247 (1999). It has been suggested (Brenner et al., *Curr. Op. Struct. Biol.*, 7(3):369-376 (1997)) that there are a limited number of folds in a given polypeptide or protein and that once a critical number of structures have been resolved, structural prediction will gain dramatically in accuracy.

Additional methods of predicting secondary structure include "threading" (Jones, D., *Curr. Opin. Struct. Biol.*, 7(3):377-87 (1997); Sippl et al., *Structure*, 4(1):15-9 (1996)), "profile analysis" (Bowie et al., *Science*, 253:164-170 (1991); Gribskov et al., *Meth. Enzym.*, 183:146-159 (1990); Gribskov et al., *Proc. Nat. Acad. Sci.*, 84(13):4355-4358 (1987)), and "evolutionary linkage" (See Home, *supra*, and Brenner, *supra*).

CD20/IgE-receptor like polypeptide analogs of the invention can be determined by comparing the amino acid sequence of CD20/IgE-receptor like polypeptide with related family members. Exemplary CD20/IgE-receptor like polypeptide related family members are human TM<sub>4</sub>, human IgERb, HURp4, IgERβ, HTPEF86, human CD20, HTM4SF5 and HTAL6. This comparison can be accomplished by using a Pileup alignment (Wisconsin GCG Program Package) or an equivalent (overlapping) comparison with multiple family members within conserved and non-conserved regions.

As shown in Figure 3, the predicted amino acid sequences of human CD20/IgE-receptor like polypeptides (SEQ ID NOS: 2 and 4) are aligned with a known human CD20/IgE-receptor family members. Other CD20/IgE-receptor like polypeptide analogs can be determined using these or other methods known to those of skill in the art. These overlapping sequences provide guidance for conservative and non-conservative amino acids substitutions resulting in additional CD20/IgE-receptor like

analogs. It will be appreciated that these amino acid substitutions can consist of naturally occurring or non-naturally occurring amino acids. For example, potential CD20/IgE-receptor like analogs may have the Gly at residue at position 86 of SEQ ID NO: 2 or 4 substituted with a Pro or Ala residue, the Phe residue at position 95 of SEQ ID NO: 2 or 4 substituted with a Leu, Val, Ile, Ala or Tyr residue, and/or the Ile residue at position 103 of SEQ ID NO: 2 or 4 substituted with a Leu, Val, Met, Ala, Phe or norleucine. In addition, potential CD20/IgE-receptor like analogs may have the Asn residue at position 121 of SEQ ID NO: 2 or 4 substituted with a Gln residue and/or the Ala residue at position 128 of SEQ ID NO: 2 or 4, substituted with a Val. Leu or Ile a residue.

Preferred CD20/IgE-receptor like polypeptide variants include glycosylation variants wherein the number and/or type of glycosylation sites has been altered compared to the amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4. In one embodiment, CD20/IgE-receptor like polypeptide variants comprise a greater or a lesser number of N-linked glycosylation sites than the amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X may be any amino acid residue except proline. The substitution(s) of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional preferred CD20/IgE-receptor like variants include cysteine variants, wherein one or more

cysteine residues are deleted from or substituted for another amino acid (e.g., serine) as compared to the amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4.

Cysteine variants are useful when CD20/IgE-receptor like polypeptides must be refolded into a biologically active conformation such as after the isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

In addition, the polypeptide comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4 or a CD20/IgE-receptor like polypeptide variant may be fused to a homologous polypeptide to form a homodimer or to a heterologous polypeptide to form a heterodimer. Heterologous peptides and polypeptides include, but are not limited to: an epitope to allow for the detection and/or isolation of a CD20/IgE-receptor like fusion polypeptide; a transmembrane receptor protein or a portion thereof, such as an extracellular domain, or a transmembrane and intracellular domain; a ligand or a portion thereof which binds to a transmembrane receptor protein; an enzyme or portion thereof which is catalytically active; a polypeptide or peptide which promotes oligomerization, such as a leucine zipper domain; a polypeptide or peptide which increases stability, such as an immunoglobulin constant region; and a polypeptide which has a therapeutic activity different from the polypeptide comprising the amino acid sequence as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4, or a CD20/IgE-receptor like polypeptide variant.

Fusions can be made either at the amino terminus or at the carboxy terminus of the polypeptide comprising the amino acid sequence set forth in either SEQ ID NO: 2 or SEQ ID NO: 4 or a CD20/IgE-receptor like polypeptide variant. Fusions may be direct with no linker or adapter molecule or indirect using

a linker or adapter molecule. A linker or adapter molecule may be one or more amino acid residues, typically up to about 20 to about 50 amino acid residues. A linker or adapter molecule may also be designed with a cleavage site for a DNA  
5 restriction endonuclease or for a protease to allow for the separation of the fused moieties. It will be appreciated that once constructed, the fusion polypeptides can be derivatized according to the methods described herein.

In a further embodiment of the invention, the polypeptide  
10 comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4 or a CD20/IgE-receptor like polypeptide variant, including a fragment, variant, and/or derivative, is fused to an an Fc region of human IgG. Antibodies comprise two functionally independent parts, a variable domain known as  
15 "Fab", which binds antigen, and a constant domain known as "Fc", which links to such effector functions as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas an Fab is short-lived. Capon et al., *Nature*, 337:525-31 (1989). When constructed together with a  
20 therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation and perhaps even placental transfer. *Id.* Table II summarizes the use of certain Fc fusions known in the art, including materials and methods  
25 applicable to the production of fused CD20/IgE-receptor like polypeptides.

TABLE II

Fc Fusion with Therapeutic Proteins

Form of Fc	Fusion partner	Therapeutic implications	Reference
IgG1	N-terminus of CD30-L	Hodgkin's disease; anaplastic lymphoma; T-cell leukemia	U.S. Patent No. 5,480,981
Murine Fcγ2a	IL-10	anti-inflammatory; transplant rejection	Zheng et al. (1995), <i>J. Immunol.</i> , <u>154</u> : 5590-5600
IgG1	TNF receptor	septic shock	Fisher et al. (1996), <i>N. Engl. J. Med.</i> , <u>334</u> : 1697-1702; Van Zee et al., (1996), <i>J. Immunol.</i> , <u>156</u> : 2221-2230
IgG, IgA, IgM, or IgE (excluding the first domain)	TNF receptor	inflammation, autoimmune disorders	U.S. Pat. No. 5,808,029, issued September 15, 1998
IgG1	CD4 receptor	AIDS	Capon et al. (1989), <i>Nature</i> <u>337</u> : 525-531
IgG1, IgG3	N-terminus of IL-2	anti-cancer, antiviral	Harvill et al. (1995), <i>Immunotech.</i> , <u>1</u> : 95-105
IgG1	C-terminus of OPG	osteoarthritis; bone density	WO 97/23614, published July 3, 1997
IgG1	N-terminus of leptin	anti-obesity	PCT/US 97/23183, filed December 11, 1997
Human Ig Cγ1	CTLA-4	autoimmune disorders	Linsley (1991), <i>J. Exp. Med.</i> , <u>174</u> :561-569

In one example, all or a portion of the human IgG hinge, CH2 and CH3 regions may be fused at either the N-terminus or C-terminus of the CD20/IgE-receptor like polypeptides using

methods known to the skilled artisan. The resulting CD20/IgE-receptor like fusion polypeptide may be purified by use of a Protein A affinity column. Peptides and proteins fused to an Fc region have been found to exhibit a substantially greater half-life in vivo than the unfused counterpart. Also, a fusion to an Fc region allows for dimerization/multimerization of the fusion polypeptide. The Fc region may be a naturally occurring Fc region, or may be altered to improve certain qualities, such as therapeutic qualities, circulation time, reduce aggregation, etc.

Identity and similarity of related nucleic acid molecules and polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., *SIAM J. Applied Math.*, 48:1073 (1988).

Preferred methods to determine identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are described in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux et al., *Nucl. Acid. Res.*, 12:387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, and FASTA (Altschul et al., *J. Mol. Biol.*, 215:403-410 (1990)). The BLASTX program is publicly available from the National Center for

Biotechnology Information (NCBI) and other sources (*BLAST Manual*, Altschul et al. NCB/NLM/NIH Bethesda, MD 20894; Altschul et al., *supra*). The well known Smith Waterman algorithm may also be used to determine identity.

5        Certain alignment schemes for aligning two amino acid sequences may result in the matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full length sequences.  
10    Accordingly, in a preferred embodiment, the selected alignment method (GAP program) will result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

15        For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span", as determined by the algorithm). A gap opening penalty (which is calculated as 3X the average diagonal; the "average diagonal" is the average  
20    of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as  
25    PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff et al., *Atlas of Protein Sequence and Structure*, vol. 5, supp.3 (1978) for the PAM 250 comparison matrix; Henikoff et al., *Proc. Natl. Acad. Sci USA*, 89:10915-10919 (1992) for the BLOSUM 62  
30    comparison matrix) is also used by the algorithm.

      Preferred parameters for a polypeptide sequence comparison include the following:



Algorithm: Needleman et al., *J. Mol. Biol.*, 48:443-453  
(1970);

Comparison matrix: BLOSUM 62 from Henikoff et al., *Proc.  
Natl. Acad. Sci. USA*, 89:10915-10919 (1992);

5 Gap Penalty: 12

Gap Length Penalty: 4

Threshold of Similarity: 0

10 The GAP program is useful with the above parameters. The  
aforementioned parameters are the default parameters for  
polypeptide comparisons (along with no penalty for end gaps)  
using the GAP algorithm.

Preferred parameters for nucleic acid molecule sequence  
comparisons include the following:

15 Algorithm: Needleman et al., *J. Mol Biol.*, 48:443-453  
(1970);

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

20

The GAP program is also useful with the above parameters. The  
aforementioned parameters are the default parameters for  
nucleic acid molecule comparisons.

25 Other exemplary algorithms, gap opening penalties, gap  
extension penalties, comparison matrices, thresholds of  
similarity, etc. may be used,, including those set forth in  
the Program Manual, Wisconsin Package, Version 9, September,  
1997. The particular choices to be made will be apparent to  
those of skill in the art and will depend on the specific  
30 comparison to be made, such as DNA to DNA, protein to protein,  
protein to DNA; and additionally, whether the comparison is  
between given pairs of sequences (in which case GAP or BestFit  
are generally preferred) or between one sequence and a large

database of sequences (in which case FASTA or BLASTA are preferred).

### Synthesis

It will be appreciated by those skilled in the art the  
5 nucleic acid and polypeptide molecules described herein may be  
produced by recombinant and other means.

### Nucleic Acid Molecules

The nucleic acid molecules encode a polypeptide  
10 comprising the amino acid sequence of a CD20/IgE-receptor like  
polypeptide can readily be obtained in a variety of ways  
including, without limitation, chemical synthesis, cDNA or  
genomic library screening, expression library screening and/or  
PCR amplification of cDNA.

15 Recombinant DNA methods used herein are generally those  
set forth in Sambrook et al., *Molecular Cloning: A Laboratory  
Manual*, Cold Spring Harbor Laboratory Press, Cold Spring  
Harbor, NY (1989), and/or Ausubel et al., eds., *Current  
Protocols in Molecular Biology*, Green Publishers Inc. and  
20 Wiley and Sons, NY (1994). The present invention provides for  
nucleic acid molecules as described herein and methods for  
obtaining the molecules.

A gene or cDNA encoding a CD20/IgE-receptor like  
polypeptide or fragment thereof may be obtained by  
25 hybridization screening of a genomic library, or by PCR  
amplification. Where a gene encoding the amino acid sequence  
of a CD20/IgE-receptor like polypeptide has been identified  
from one species, all or a portion of that gene may be used as  
a probe to identify orthologs or related genes from the same  
30 species. The probes or primers may be used to screen cDNA  
libraries from various tissue sources believed to express the  
CD20/IgE-receptor like polypeptide. In addition, part or all  
of a nucleic acid molecule having the sequence as set forth in

either SEQ ID NO: 1 or SEQ ID NO: 3 may be used to screen a genomic library to identify and isolate a gene encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide. Typically, conditions of moderate or high stringency will be  
5 employed for screening to minimize the number of false positives obtained from the screen.

Nucleic acid molecules encoding the amino acid sequence of CD20/IgE-receptor like polypeptides may also be identified by expression cloning which employs the detection of positive  
10 clones based upon a property of the expressed protein. Typically, nucleic acid libraries are screened by the binding of an antibody or other binding partner (e.g., receptor or ligand) to cloned proteins which are expressed and displayed on a host cell surface. The antibody or binding partner is  
15 modified with a detectable label to identify those cells expressing the desired clone.

Recombinant expression techniques conducted in accordance with the descriptions set forth below may be followed to produce these polynucleotides and to express the encoded  
20 polypeptides. For example, by inserting a nucleic acid sequence which encodes the amino acid sequence of a CD20/IgE-receptor like polypeptide into an appropriate vector, one skilled in the art can readily produce large quantities of the desired nucleotide sequence. The sequences can then be used  
25 to generate detection probes or amplification primers. Alternatively, a polynucleotide encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide can be inserted into an expression vector. By introducing the expression vector into an appropriate host, the encoded  
30 CD20/IgE-receptor like polypeptide may be produced in large amounts.

Another method for obtaining a suitable nucleic acid sequence is the polymerase chain reaction (PCR). In this method, cDNA is prepared from poly(A)+ RNA or total RNA using

the enzyme reverse transcriptase. Two primers, typically complementary to two separate regions of cDNA (oligonucleotides) encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide, are then added to the cDNA  
5 along with a polymerase such as *Taq* polymerase, and the polymerase amplifies the cDNA region between the two primers.

Another means of preparing a nucleic acid molecule encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide, including a fragment or variant, is chemical  
10 synthesis using methods well known to the skilled artisan such as those described by Engels *et al.*, *Angew. Chem. Intl. Ed.*, 28:716-734 (1989). These methods include, *inter alia*, the phosphotriester, phosphoramidite, and H-phosphonate methods for nucleic acid synthesis. A preferred method for such  
15 chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, the DNA encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides can be  
20 synthesized as several fragments using these methods. The fragments can then be ligated together to form the full length nucleotide sequence of a CD20/IgE-receptor like polypeptide. Usually, the DNA fragment encoding the amino terminus of the polypeptide will have an ATG, which encodes a methionine  
25 residue. This methionine may or may not be present on the mature form of the CD20/IgE-receptor like polypeptide, depending on whether the polypeptide produced in the host cell is designed to be secreted from that cell. Other methods known to the skilled artisan may be used as well.

30 In some cases, it may be desirable to prepare nucleic acid molecules encoding CD20/IgE-receptor like polypeptide variants. Nucleic acid molecules encoding variants may be produced using site directed mutagenesis, PCR amplification, or other appropriate methods, where the primer(s) have the desired point  
35 mutations (see Sambrook *et al.*, *supra*, and Ausubel *et al.*,

supra, for descriptions of mutagenesis techniques). Chemical synthesis using methods described by Engels et al., supra, may also be used to prepare such variants. Other methods known to the skilled artisan may be used as well.

5 In certain embodiments, nucleic acid variants contain codons which have been altered for the optimal expression of a CD20/IgE-receptor like polypeptide in a given host cell. Particular codon alterations will depend upon the CD20/IgE-receptor like polypeptide(s) and host cell(s) selected for  
10 expression. Such "codon optimization" can be carried out by a variety of methods, for example, by selecting codons which are preferred for use in highly expressed genes in a given host cell. Computer algorithms which incorporate codon frequency tables such as "Ecohigh.cod" for codon preference of highly  
15 expressed bacterial genes may be used and are provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI. Other useful codon frequency tables include "Celegans\_high.cod", "Celegans\_low.cod", "Drosophila\_high.cod", "Human\_high.cod", "Maize\_high.cod", and  
20 "Yeast\_high.cod".

In other embodiments, nucleic acid molecules encode CD20/IgE-receptor like variants with conservative amino acid substitutions as described herein, CD20/IgE-receptor like variants comprising an addition and/or a deletion of one or  
25 more N-linked or O-linked glycosylation sites, CD20/IgE-receptor like variants having deletions and/or substitutions of one or more cysteine residues, or CD20/IgE-receptor like polypeptide fragments as described herein. In addition, nucleic acid molecules may encode any combination of CD20/IgE-receptor like variants, fragments, and fusion polypeptides  
30 described herein.

#### Vectors and Host Cells

A nucleic acid molecule encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide may be inserted into

an appropriate expression vector using standard ligation techniques. The vector is typically selected to be functional in the particular host cell employed (*i.e.*, the vector is compatible with the host cell machinery such that  
5 amplification of the gene and/or expression of the gene can occur). A nucleic acid molecule encoding the amino acid sequence of a CD20/IgE-receptor like polypeptide may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems), and/or eukaryotic host cells. Selection of the host  
10 cell will depend in part on whether a CD20/IgE-receptor like polypeptide is to be post-translationally modified (*e.g.*, glycosylated and/or phosphorylated). If so, yeast, insect, or mammalian host cells are preferable. For a review of expression vectors, see *Meth. Enz.*, v.185, D.V. Goeddel, ed.  
15 Academic Press Inc., San Diego, CA (1990).

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking  
20 sequences" in certain embodiments will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor splice site, a  
25 sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Each of these sequences is discussed below.

Optionally, the vector may contain a "tag"-encoding sequence, *i.e.*, an oligonucleotide molecule located at the 5' or 3' end of the CD20/IgE-receptor like polypeptide coding sequence; the oligonucleotide sequence encodes polyHis (such as hexaHis), or other "tag" such as FLAG, HA (hemagglutinin  
35 Influenza virus) or myc for which commercially available

antibodies exist. This tag is typically fused to the polypeptide upon expression of the polypeptide, and can serve as a means for affinity purification of the CD20/IgE-receptor like polypeptide from the host cell. Affinity purification  
5 can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can subsequently be removed from the purified CD20/IgE-receptor like polypeptide by various means such as using certain peptidases for cleavage.

10 Flanking sequences may be homologous (*i.e.*, from the same species and/or strain as the host cell), heterologous (*i.e.*, from a species other than the host cell species or strain), hybrid (*i.e.*, a combination of flanking sequences from more than one source) or synthetic, or the flanking sequences may  
15 be native sequences which normally function to regulate CD20/IgE-receptor like polypeptide expression. As such, the source of a flanking sequence may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence is  
20 functional in, and can be activated by, the host cell machinery.

The flanking sequences useful in the vectors of this invention may be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein other  
25 than the CD20/IgE-receptor like gene flanking sequences will have been previously identified by mapping and/or by restriction endonuclease digestion and can thus be isolated from the proper tissue source using the appropriate restriction endonucleases. In some cases, the full nucleotide  
30 sequence of a flanking sequence may be known. Here, the flanking sequence may be synthesized using the methods described herein for nucleic acid synthesis or cloning.

Where all or only a portion of the flanking sequence is known, it may be obtained using PCR and/or by screening a

genomic library with suitable oligonucleotide and/or flanking sequence fragments from the same or another species. Where the flanking sequence is not known, a fragment of DNA containing a flanking sequence may be isolated from a larger  
5 piece of DNA that may contain, for example, a coding sequence or even another gene or genes. Isolation may be accomplished by restriction endonuclease digestion to produce the proper DNA fragment followed by isolation using agarose gel purification, Qiagen® column chromatography (Chatsworth, CA),  
10 or other methods known to the skilled artisan. The selection of suitable enzymes to accomplish this purpose will be readily apparent to one of ordinary skill in the art.

An origin of replication is typically a part of those prokaryotic expression vectors purchased commercially, and the  
15 origin aids in the amplification of the vector in a host cell. Amplification of the vector to a certain copy number can, in some cases, be important for the optimal expression of a CD20/IgE-receptor like polypeptide. If the vector of choice does not contain an origin of replication site, one may be  
20 chemically synthesized based on a known sequence, and ligated into the vector. For example, the origin of replication from the plasmid pBR322 (Product No. 303-3s, New England Biolabs, Beverly, MA) is suitable for most Gram-negative bacteria and various origins (e.g., SV40, polyoma, adenovirus, vesicular  
25 stomatitis virus (VSV) or papillomaviruses such as HPV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (for example, the SV40 origin is often used only because it contains the early promoter).

30 A transcription termination sequence is typically located 3' of the end of a polypeptide coding region and serves to terminate transcription. Usually, a transcription termination sequence in prokaryotic cells is a G-C rich fragment followed by a poly T sequence. While the sequence is easily cloned  
35 from a library or even purchased commercially as part of a



vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described herein.

5 A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, tetracycline, or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not  
10 available from complex media. Preferred selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the tetracycline resistance gene. A neomycin resistance gene may also be used for selection in prokaryotic and eukaryotic host cells.

15 Other selection genes may be used to amplify the gene which will be expressed. Amplification is the process wherein genes which are in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant  
20 cells. Examples of suitable selectable markers for mammalian cells include dihydrofolate reductase (DHFR) and thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of the selection gene present in  
25 the vector. Selection pressure is imposed by culturing the transformed cells under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to the amplification of both the selection gene and the DNA that encodes a CD20/IgE-receptor like  
30 polypeptide. As a result, increased quantities of CD20/IgE-receptor like polypeptide are synthesized from the amplified DNA.

A ribosome binding site is usually necessary for translation initiation of mRNA and is characterized by a

Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). The element is typically located 3' to the promoter and 5' to the coding sequence of a CD20/IgE-receptor like polypeptide to be expressed. The Shine-Dalgarno sequence  
5 is varied but is typically a polypurine (i.e., having a high A-G content). Many Shine-Dalgarno sequences have been identified, each of which can be readily synthesized using methods set forth herein and used in a prokaryotic vector.

A leader, or signal, sequence may be used to direct a  
10 CD20/IgE-receptor like polypeptide out of the host cell. Typically, a nucleotide sequence encoding the signal sequence is positioned in the coding region of a CD20/IgE-receptor like nucleic acid molecule, or directly at the 5' end of a CD20/IgE-receptor like polypeptide coding region. Many signal  
15 sequences have been identified, and any of those that are functional in the selected host cell may be used in conjunction with a CD20/IgE-receptor like nucleic acid molecule. Therefore, a signal sequence may be homologous (naturally occurring) or heterologous to a CD20/IgE-receptor  
20 like gene or cDNA. Additionally, a signal sequence may be chemically synthesized using methods described herein. In most cases, the secretion of a CD20/IgE-receptor like polypeptide from the host cell via the presence of a signal peptide will result in the removal of the signal peptide from  
25 the secreted CD20/IgE-receptor like polypeptide. The signal sequence may be a component of the vector, or it may be a part of a CD20/IgE-receptor like nucleic acid molecule that is inserted into the vector.

Included within the scope of this invention is the use of  
30 either a nucleotide sequence encoding a native CD20/IgE-receptor like polypeptide signal sequence joined to a CD20/IgE-receptor like polypeptide coding region or a nucleotide sequence encoding a heterologous signal sequence joined to a CD20/IgE-receptor like polypeptide coding region.  
35 The heterologous signal sequence selected should be one that

is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell. For prokaryotic host cells that do not recognize and process the native CD20/IgE-receptor like polypeptide signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin II leaders. For yeast secretion, the native CD20/IgE-receptor like polypeptide signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders. In mammalian cell expression the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.

In some cases, such as where glycosylation is desired in a eukaryotic host cell expression system, one may manipulate the various presequences to improve glycosylation or yield. For example, one may alter the peptidase cleavage site of a particular signal peptide, or add presequences, which also may affect glycosylation. The final protein product may have, in the -1 position (relative to the first amino acid of the mature protein) one or more additional amino acids incident to expression, which may not have been totally removed. For example, the final protein product may have one or two amino acid residues found in the peptidase cleavage site, attached to the N-terminus. Alternatively, use of some enzyme cleavage sites may result in a slightly truncated form of the desired CD20/IgE-receptor like polypeptide, if the enzyme cuts at such area within the mature polypeptide.

In many cases, transcription of a nucleic acid molecule is increased by the presence of one or more introns in the vector; this is particularly true where a polypeptide is produced in eukaryotic host cells, especially mammalian host cells. The introns used may be naturally occurring within the CD20/IgE-receptor like gene, especially where the gene used is a full length genomic sequence or a fragment thereof. Where the intron is not naturally occurring within the gene (as for

most cDNAs), the intron(s) may be obtained from another source. The position of the intron with respect to flanking sequences and the CD20/IgE-receptor like gene is generally important, as the intron must be transcribed to be effective.

5 Thus, when a CD20/IgE-receptor like cDNA molecule is being transcribed, the preferred position for the intron is 3' to the transcription start site, and 5' to the polyA transcription termination sequence. Preferably, the intron or introns will be located on one side or the other (i.e., 5' or  
10 3') of the cDNA such that it does not interrupt the coding sequence. Any intron from any source, including any viral, prokaryotic and eukaryotic (plant or animal) organisms, may be used to practice this invention, provided that it is compatible with the host cell(s) into which it is inserted.  
15 Also included herein are synthetic introns. Optionally, more than one intron may be used in the vector.

The expression and cloning vectors of the present invention will each typically contain a promoter that is recognized by the host organism and operably linked to the  
20 molecule encoding a CD20/IgE-receptor like polypeptide. Promoters are untranscribed sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription of the structural gene. Promoters are conventionally grouped into  
25 one of two classes, inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature. Constitutive  
30 promoters, on the other hand, initiate continual gene product production; that is, there is little or no control over gene expression. A large number of promoters, recognized by a variety of potential host cells, are well known. A suitable promoter is operably linked to the DNA encoding a CD20/IgE-  
35 receptor like polypeptide by removing the promoter from the

source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector. The native CD20/IgE-receptor like gene promoter sequence may be used to direct amplification and/or expression of a CD20/IgE-receptor like nucleic acid molecule. A heterologous promoter is preferred, however, if it permits greater transcription and higher yields of the expressed protein as compared to the native promoter, and if it is compatible with the host cell system that has been selected for use.

Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems; alkaline phosphatase, a tryptophan (trp) promoter system; and hybrid promoters such as the tac promoter. Other known bacterial promoters are also suitable. Their sequences have been published, thereby enabling one skilled in the art to ligate them to the desired DNA sequence(s), using linkers or adapters as needed to supply any useful restriction sites.

Suitable promoters for use with yeast hosts are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for use with mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, e.g., heat-shock promoters and the actin promoter.

Additional promoters which may be of interest in controlling CD20/IgE-receptor like gene transcription include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature*, 290:304-310, 1981); the CMV promoter; the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-

797, 1980); the herpes thymidine kinase promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA*, 78:144-1445, 1981); the regulatory sequences of the metallothionine gene (Brinster et al., *Nature*, 296:39-42, 1982); prokaryotic expression vectors  
5 such as the beta-lactamase promoter (Villa-Kamaroff, et al., *Proc. Natl. Acad. Sci. USA*, 75:3727-3731, 1978); or the tac promoter (DeBoer, et al., *Proc. Natl. Acad. Sci. USA*, 80:21-25, 1983). Also of interest are the following animal transcriptional control regions, which exhibit tissue  
10 specificity and have been utilized in transgenic animals: the elastase I gene control region which is active in pancreatic acinar cells (Swift et al., *Cell*, 38:639-646, 1984; Ornitz et al., *Cold Spring Harbor Symp. Quant. Biol.*, 50:399-409 (1986); MacDonald, *Hepatology*, 7:425-515, 1987); the insulin gene  
15 control region which is active in pancreatic beta cells (Hanahan, *Nature*, 315:115-122, 1985); the immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., *Cell*, 38:647-658 (1984); Adames et al., *Nature*, 318:533-538 (1985); Alexander et al., *Mol. Cell. Biol.*,  
20 7:1436-1444, 1987); the mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., *Cell*, 45:485-495, 1986); the albumin gene control region which is active in liver (Pinkert et al., *Genes and Devel.*, 1:268-276, 1987); the alphafetoprotein gene  
25 control region which is active in liver (Krumlauf et al., *Mol. Cell. Biol.*, 5:1639-1648, 1985; Hammer et al., *Science*, 235:53-58, 1987); the alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., *Genes and Devel.*, 1:161-171, 1987); the beta-globin gene control region which is  
30 active in myeloid cells (Mogram et al., *Nature*, 315:338-340, 1985; Kollias et al., *Cell*, 46:89-94, 1986); the myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., *Cell*, 48:703-712, 1987); the myosin light chain-2 gene control region which is active  
35 in skeletal muscle (Sani, *Nature*, 314:283-286, 1985); and the

gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., Science, 234:1372-1378, 1986).

5 An enhancer sequence may be inserted into the vector to increase the transcription of a DNA encoding a CD20/IgE-receptor like polypeptide of the present invention by higher eukaryotes. Enhancers are cis-acting elements of DNA, usually about 10-300 bp in length, that act on the promoter to increase transcription. Enhancers are relatively orientation and position independent. They have been found 5' and 3' to the transcription unit. Several enhancer sequences available from mammalian genes are known (e.g., globin, elastase, albumin, alpha-feto-protein and insulin). Typically, however, an enhancer from a virus will be used. The SV40 enhancer, the 10 cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers are exemplary enhancing elements for the activation of eukaryotic promoters. While an enhancer may be spliced into the vector at a position 5' or 3' to a CD20/IgE-receptor like nucleic acid molecule, it is typically 15 located at a site 5' from the promoter. 20

Expression vectors of the invention may be constructed from a starting vector such as a commercially available vector. Such vectors may or may not contain all of the desired flanking sequences. Where one or more of the desired 25 flanking sequences are not already present in the vector, they may be individually obtained and ligated into the vector. Methods used for obtaining each of the flanking sequences are well known to one skilled in the art.

Preferred vectors for practicing this invention are those 30 which are compatible with bacterial, insect, and mammalian host cells. Such vectors include, *inter alia*, pCRII, pCR3, and pcDNA3.1 (Invitrogen Company, Carlsbad, CA), pBSII (Stratagene Company, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2

(Clontech, Palo Alto, CA), pETL (BlueBacII; Invitrogen), pDSR-alpha (PCT Publication No. WO90/14363) and pFastBacDual (Gibco/BRL, Grand Island, NY).

Additional suitable vectors include, but are not limited to, cosmids, plasmids or modified viruses, but it will be appreciated that the vector system must be compatible with the selected host cell. Such vectors include, but are not limited to plasmids such as Bluescript<sup>®</sup> plasmid derivatives (a high copy number ColE1-based phagemid, Stratagene Cloning Systems Inc., La Jolla CA), PCR cloning plasmids designed for cloning Taq-amplified PCR products (e.g., TOPO<sup>™</sup> TA Cloning<sup>®</sup> Kit, PCR2.1<sup>®</sup> plasmid derivatives, Invitrogen, Carlsbad, CA), and mammalian, yeast, or virus vectors such as a baculovirus expression system (pBacPAK plasmid derivatives, Clontech, Palo Alto, CA). The recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation or other known techniques.

After the vector has been constructed and a nucleic acid molecule encoding a CD20/IgE-receptor like polypeptide has been inserted into the proper site of the vector, the completed vector may be inserted into a suitable host cell for amplification and/or polypeptide expression. The transformation of an expression vector for a CD20/IgE-receptor like polypeptide into a selected host cell may be accomplished by well known methods including methods such as transfection, infection, calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method or other known techniques. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook et al., *supra*.

Host cells may be prokaryotic host cells (such as *E. coli*) or eukaryotic host cells (such as a yeast cell, an insect cell or a vertebrate cell). The host cell, when



cultured under appropriate conditions, synthesizes a CD20/IgE-receptor like polypeptide which can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted). The selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity, such as glycosylation or phosphorylation, and ease of folding into a biologically active molecule.

A number of suitable host cells are known in the art and many are available from the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209. Examples include, but are not limited to, mammalian cells, such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61) CHO DHFR-cells (Urlaub et al., *Proc. Natl. Acad. Sci. USA*, 97:4216-4220 (1980)), human embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRL1573), or 3T3 cells (ATCC No. CCL92). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines, are the monkey COS-1 (ATCC No. CRL1650) and COS-7 cell lines (ATCC No. CRL1651), and the CV-1 cell line (ATCC No. CCL70). Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or may contain a dominantly acting selection gene. Other suitable mammalian cell lines include but are not limited to, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines, which are available from the ATCC. Each of these cell lines is known by and available to those skilled in the

art of protein expression.

Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of *E. coli* (e.g., HB101, (ATCC No. 33694) DH5 $\alpha$ , DH10, 5 and MC1061 (ATCC No. 53338)) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas spp.*, other *Bacillus spp.*, *Streptomyces spp.*, and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the 10 art are also available as host cells for the expression of the polypeptides of the present invention. Preferred yeast cells include, for example, *Saccharomyces cerivisiae* and *Pichia pastoris*.

Additionally, where desired, insect cell systems may be 15 utilized in the methods of the present invention. Such systems are described for example in Kitts et al., *Biotechniques*, 14:810-817 (1993); Lucklow, *Curr. Opin. Biotechnol.*, 4:564-572 (1993); and Lucklow et al. (*J. Virol.*, 67:4566-4579 (1993)). Preferred insect cells are Sf-9 and Hi5 20 (Invitrogen, Carlsbad, CA).

One may also use transgenic animals to express glycosylated CD20/IgE-receptor like polypeptides. For example, one may use a transgenic milk-producing animal (a cow or goat, for example) and obtain the present glycosylated 25 polypeptide in the animal milk. One may also use plants to produce CD20/IgE-receptor like polypeptides, however, in general, the glycosylation occurring in plants is different from that produced in mammalian cells, and may result in a glycosylated product which is not suitable for human 30 therapeutic use.

### Polypeptide Production

Host cells comprising a CD20/IgE-receptor like polypeptide expression vector may be cultured using standard media well known to the skilled artisan. The media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells include, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells include Roswell Park Memorial Institute medium 1640 (RPMI 1640), Minimal Essential Medium (MEM) and/or Dulbecco's Modified Eagle Medium (DMEM), all of which may be supplemented with serum and/or growth factors as indicated by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate and/or fetal calf serum, as necessary.

Typically, an antibiotic or other compound useful for selective growth of transformed cells is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin. Other compounds for selective growth include ampicillin, tetracycline, and neomycin.

The amount of a CD20/IgE-receptor like polypeptide produced by a host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, high performance liquid chromatography (HPLC) separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

If a CD20/IgE-receptor like polypeptide has been designed to be secreted from the host cells, the majority of polypeptide may be found in the cell culture medium. If however, the CD20/IgE-receptor like polypeptide is not  
5 secreted from the host cells, it will be present in the cytoplasm and/or the nucleus (for eukaryotic host cells) or in the cytosol (for bacterial host cells).

For a CD20/IgE-receptor like polypeptide situated in the host cell cytoplasm and/or the nucleus (for eukaryotic host  
10 cells) or in the cytosol (for bacterial host cells) the host cells are typically disrupted mechanically or with a detergent to release the intracellular contents into a buffered solution. CD20/IgE-receptor like polypeptides can then be isolated from this solution.

15 If a CD20/IgE-receptor like polypeptide is produced intracellularly, the intracellular material (including inclusion bodies for gram-negative bacteria) can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be lysed to  
20 release the contents of the periplasm/cytoplasm by French press, homogenization, and/or sonication followed by centrifugation.

If a CD20/IgE-receptor like polypeptide has formed inclusion bodies in the cytosol, the inclusion bodies can  
25 often bind to the inner and/or outer cellular membranes and thus will be found primarily in the pellet material after centrifugation. The pellet material can then be treated at pH extremes or with a chaotropic agent such as a detergent, guanidine, guanidine derivatives, urea, or urea derivatives in  
30 the presence of a reducing agent such as dithiothreitol at alkaline pH or tris carboxyethyl phosphine at acid pH to release, break apart, and solubilize the inclusion bodies. The CD20/IgE-receptor like polypeptide in its now soluble form can then be analyzed using gel electrophoresis,

immunoprecipitation or the like. If it is desired to isolate the CD20/IgE-receptor like polypeptide, isolation may be accomplished using standard methods such as those described herein and in Marston et al., *Meth. Enz.*, 182:264-275 (1990).

5 In some cases, a CD20/IgE-receptor like polypeptide may not be biologically active upon isolation. Various methods for "refolding" or converting the polypeptide to its tertiary structure and generating disulfide linkages can be used to restore biological activity. Such methods include exposing  
10 the solubilized polypeptide to a pH usually above 7 and in the presence of a particular concentration of a chaotrope. The selection of chaotrope is very similar to the choices used for inclusion body solubilization, but usually the chaotrope is used at a lower concentration and is not necessarily the same  
15 as chaotropes used for the solubilization. In most cases the refolding/oxidation solution will also contain a reducing agent or the reducing agent plus its oxidized form in a specific ratio to generate a particular redox potential allowing for disulfide shuffling to occur in the formation of  
20 the protein's cysteine bridge(s). Some of the commonly used redox couples include cysteine/cystamine, glutathione (GSH)/dithiobis GSH, cupric chloride, dithiothreitol (DTT)/dithiane DTT, and 2-2mercaptoethanol (BME)/dithio-b (ME).. A cosolvent may be used to increase the efficiency of the  
25 refolding, and the more common reagents used for this purpose include glycerol, polyethylene glycol of various molecular weights, arginine and the like.

If inclusion bodies are not formed to a significant degree upon expression of a CD20/IgE-receptor like  
30 polypeptide, then the polypeptide will be found primarily in the supernatant after centrifugation of the cell homogenate. The polypeptide may be further isolated from the supernatant using methods such as those described herein.

The purification of a CD20/IgE-receptor like polypeptide from solution can be accomplished using a variety of techniques. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine (CD20/IgE-receptor like polypeptide/hexaHis) or other small peptide such as FLAG (Eastman Kodak Co., New Haven, CT) or *myc* (Invitrogen, Carlsbad, CA) at either its carboxyl or amino terminus, it may be purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag.

For example, polyhistidine binds with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen® nickel columns) can be used for purification of CD20/IgE-receptor like polypeptide/polyHis. See for example, Ausubel et al., eds., *Current Protocols in Molecular Biology*, Section 10.11.8, John Wiley & Sons, New York (1993).

Additionally, the CD20/IgE-receptor like polypeptide may be purified through the use of a monoclonal antibody which is capable of specifically recognizing and binding to the CD20/IgE-receptor like polypeptide.

Suitable procedures for purification thus include, without limitation, affinity chromatography, immunoaffinity chromatography, ion exchange chromatography, molecular sieve chromatography, High Performance Liquid Chromatography (HPLC), electrophoresis (including native gel electrophoresis) followed by gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific, San Francisco, CA). In some cases, two or more purification techniques may be combined to achieve increased purity.

CD20/IgE-receptor like polypeptides, including fragments, variants and/or derivatives thereof may also be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, such as those

set forth by Merrifield et al., *J. Am. Chem. Soc.*, 85:2149 (1963), Houghten et al., *Proc Natl Acad. Sci. USA*, 82:5132 (1985), and Stewart and Young, *Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, IL (1984). Such polypeptides  
5 may be synthesized with or without a methionine on the amino terminus. Chemically synthesized CD20/IgE-receptor like polypeptides may be oxidized using methods set forth in these references to form disulfide bridges. Chemically synthesized CD20/IgE-receptor like polypeptides are expected to have  
10 comparable biological activity to the corresponding CD20/IgE-receptor like polypeptides produced recombinantly or purified from natural sources, and thus may be used interchangeably with a recombinant or natural CD20/IgE-receptor like polypeptide.

15 Another means of obtaining a CD20/IgE-receptor like polypeptide is via purification from biological samples such as source tissues and/or fluids in which the CD20/IgE-receptor like polypeptide is naturally found. Such purification can be conducted using methods for protein purification as described  
20 herein. The presence of the CD20/IgE-receptor like polypeptide during purification may be monitored using, for example, an antibody prepared against recombinantly produced CD20/IgE-receptor like polypeptide or peptide fragments thereof.

25 A number of additional methods for producing nucleic acids and polypeptides are known in the art, and can be used to produce polypeptides having specificity for CD20/IgE-receptor like. See for example, Roberts et al., *Proc. Natl. Acad. Sci.*, 94:12297-12303 (1997), which describes the  
30 production of fusion proteins between an mRNA and its encoded peptide. See also Roberts, R., *Curr. Opin. Chem. Biol.*, 3:268-273 (1999). Additionally, U.S. patent No. 5,824,469 describes methods of obtaining oligonucleotides capable of carrying out a specific biological function. The procedure  
35 involves generating a heterogeneous pool of oligonucleotides,

each having a 5' randomized sequence, a central preselected sequence, and a 3' randomized sequence. The resulting heterogeneous pool is introduced into a population of cells that do not exhibit the desired biological function.

- 5 Subpopulations of the cells are then screened for those which exhibit a predetermined biological function. From that subpopulation, oligonucleotides capable of carrying out the desired biological function are isolated.

U.S. Patent Nos. 5,763,192, 5,814,476, 5,723,323, and  
10 5,817,483 describe processes for producing peptides or polypeptides. This is done by producing stochastic genes or fragments thereof, and then introducing these genes into host cells which produce one or more proteins encoded by the stochastic genes. The host cells are then screened to  
15 identify those clones producing peptides or polypeptides having the desired activity.

Another method for producing peptides or polypeptides is described in PCT/US98/20094 (WO99/15650) filed by Athersys, Inc. Known as "Random Activation of Gene Expression for Gene  
20 Discovery" (RAGE-GD), the process involves the activation of endogenous gene expression or over-expression of a gene by in situ recombination methods. For example, expression of an endogenous gene is activated or increased by integrating a regulatory sequence into the target cell which is capable of  
25 activating expression of the gene by non-homologous or illegitimate recombination. The target DNA is first subjected to radiation, and a genetic promoter inserted. The promoter eventually locates a break at the front of a gene, initiating transcription of the gene. This results in expression of the  
30 desired peptide or polypeptide.

It will be appreciated that these methods can also be used to create comprehensive CD20/IgE-receptor like protein expression libraries, which can subsequently be used for high



throughput phenotypic screening in a variety of assays, such as biochemical assays, cellular assays, and whole organism assays (e.g., plant, mouse, etc.).

### Chemical Derivatives

5 Chemically modified derivatives of the CD20/IgE-receptor like polypeptides may be prepared by one skilled in the art, given the disclosures set forth hereinbelow. CD20/IgE-receptor like polypeptide derivatives are modified in a manner that is different, either in the type or location of the  
10 molecules naturally attached to the polypeptide. Derivatives may include molecules formed by the deletion of one or more naturally-attached chemical groups. The polypeptide comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4, or a CD20/IgE-receptor like polypeptide variant  
15 may be modified by the covalent attachment of one or more polymers. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Included within the scope of  
20 suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

The polymers each may be of any molecular weight and may be branched or unbranched. The polymers each typically have  
25 an average molecular weight of between about 2kDa to about 100kDa (the term "about" indicating that in preparations of a water soluble polymer, some molecules will weigh more, some less, than the stated molecular weight). The average molecular weight of each polymer preferably is between about  
30 5kDa and about 50kDa, more preferably between about 12kDa and about 40kDa and most preferably between about 20kDa and about 35kDa.

Suitable water soluble polymers or mixtures thereof include, but are not limited to, N-linked or O-linked carbohydrates, sugars, phosphates, polyethylene glycol (PEG) (including the forms of PEG that have been used to derivatize  
5 proteins, including mono-(C<sub>1</sub>-C<sub>10</sub>) alkoxy- or aryloxy-polyethylene glycol), monomethoxy-polyethylene glycol, dextran (such as low molecular weight dextran, of, for example about 6 kD), cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol  
10 homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional crosslinking molecules which may be used to prepare covalently attached multimers of the polypeptide  
15 comprising the amino acid sequence of either SEQ ID NO: 2 or SEQ ID NO: 4 or a CD20/IgE-receptor like polypeptide variant.

In general, chemical derivatization may be performed under any suitable condition used to react a protein with an activated polymer molecule. Methods for preparing chemical  
20 derivatives of polypeptides will generally comprise the steps of (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions whereby the polypeptide comprising the amino acid sequence of either SEQ ID NO: 2 or  
25 SEQ ID NO: 4, or a CD20/IgE-receptor like polypeptide variant becomes attached to one or more polymer molecules, and (b) obtaining the reaction product(s). The optimal reaction conditions will be determined based on known parameters and the desired result. For example, the larger the ratio of  
30 polymer molecules:protein, the greater the percentage of attached polymer molecule. In one embodiment, the CD20/IgE-receptor like polypeptide derivative may have a single polymer molecule moiety at the amino terminus. See, for example, U.S. Patent No. 5,234,784.

The pegylation of the polypeptide specifically may be carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis et al., *Focus on Growth Factors*, 3:4-10 (1992); EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. For example, pegylation may be carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein. For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono C<sub>1</sub>-C<sub>10</sub> alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

In another embodiment, CD20/IgE-receptor like polypeptides may be chemically coupled to biotin, and the biotin/CD20/IgE-receptor like polypeptide molecules which are conjugated are then allowed to bind to avidin, resulting in tetravalent avidin/biotin/CD20/IgE-receptor like polypeptide molecules. CD20/IgE-receptor like polypeptides may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNP-IgM to form decameric conjugates with a valency of 10.

Generally, conditions which may be alleviated or modulated by the administration of the present CD20/IgE-receptor like polypeptide derivatives include those described herein for CD20/IgE-receptor like polypeptides. However, the CD20/IgE-receptor like polypeptide derivatives disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as

increased or decreased half-life, as compared to the non-derivatized molecules.

### Genetically Engineered Non-Human Animals

5 Additionally included within the scope of the present invention are non-human animals such as mice, rats, or other rodents, rabbits, goats, or sheep, or other farm animals, in which the gene (or genes) encoding the native CD20/IgE-receptor like polypeptide has (have) been disrupted ("knocked out") such that the level of expression of this gene or genes  
10 is (are) significantly decreased or completely abolished. Such animals may be prepared using techniques and methods such as those described in U.S. Patent No. 5,557,032.

The present invention further includes non-human animals such as mice, rats, or other rodents, rabbits, goats, sheep,  
15 or other farm animals, in which either the native form of the CD20/IgE-receptor like gene(s) for that animal or a heterologous CD20/IgE-receptor like gene(s) is (are) over-expressed by the animal, thereby creating a "transgenic" animal. Such transgenic animals may be prepared using well  
20 known methods such as those described in U.S. Patent No 5,489,743 and PCT application No. WO94/28122.

The present invention further includes non-human animals in which the promoter for one or more of the CD20/IgE-receptor like polypeptides of the present invention is either activated  
25 or inactivated (e.g., by using homologous recombination methods) to alter the level of expression of one or more of the native CD20/IgE-receptor like polypeptides.

These non-human animals may be used for drug candidate screening. In such screening, the impact of a drug candidate  
30 on the animal may be measured. For example, drug candidates may decrease or increase the expression of the CD20/IgE-receptor like gene. In certain embodiments, the amount of

CD20/IgE-receptor like polypeptide, that is produced may be measured after the exposure of the animal to the drug candidate. Additionally, in certain embodiments, one may detect the actual impact of the drug candidate on the animal.

- 5 For example, the overexpression of a particular gene may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease expression of the gene or its ability to prevent or inhibit a pathological condition. In other
- 10 examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product or its ability to
- 15 prevent or inhibit a pathological condition.

#### Microarray

- It will be appreciated that DNA microarray technology can be utilized in accordance with the present invention. DNA
- 20 microarrays are miniature, high density arrays of nucleic acids positioned on a solid support, such as glass. Each cell or element within the array has numerous copies of a single species of DNA which acts as a target for hybridization for its cognate mRNA. In expression profiling using DNA
- 25 microarray technology, mRNA is first extracted from a cell or tissue sample and then converted enzymatically to fluorescently labeled cDNA. This material is hybridized to the microarray and unbound cDNA is removed by washing. The expression of discrete genes represented on the array is then
- 30 visualized by quantitating the amount of labeled cDNA which is specifically bound to each target DNA. In this way, the expression of thousands of genes can be quantitated in a high throughput, parallel manner from a single sample of biological material.

This high throughput expression profiling has a broad range of applications with respect to the CD20/IgE-receptor like molecules of the invention, including, but not limited to: the identification and validation of CD20/IgE-receptor like disease-related genes as targets for therapeutics; molecular toxicology of CD20/IgE-receptor like molecules and inhibitors thereof; stratification of populations and generation of surrogate markers for clinical trials; and enhancing CD20/IgE-receptor like-related small molecule drug discovery by aiding in the identification of selective compounds in high throughput screens (HTS).

### Selective Binding Agents

As used herein, the term "selective binding agent" refers to a molecule which has specificity for one or more CD20/IgE-receptor like polypeptides. Suitable selective binding agents include, but are not limited to, antibodies and derivatives thereof, polypeptides, and small molecules. Suitable selective binding agents may be prepared using methods known in the art. An exemplary CD20/IgE-receptor like polypeptide selective binding agent of the present invention is capable of binding a certain portion of the CD20/IgE-receptor like polypeptide thereby inhibiting the binding of the polypeptide to the CD20/IgE-receptor like polypeptide receptor(s).

Selective binding agents such as antibodies and antibody fragments that bind CD20/IgE-receptor like polypeptides are within the scope of the present invention. The antibodies may be polyclonal including monospecific polyclonal, monoclonal (MAbs), recombinant, chimeric, humanized such as CDR-grafted, human, single chain, and/or bispecific, as well as fragments, variants or derivatives thereof. Antibody fragments include those portions of the antibody which bind to an epitope on the CD20/IGE-RECEPTOR LIKE polypeptide. Examples of such fragments include Fab and F(ab') fragments generated by

enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions.

Polyclonal antibodies directed toward a CD20/IgE-receptor like polypeptide generally are produced in animals (e.g., rabbits or mice) by means of multiple subcutaneous or intraperitoneal injections of CD20/IgE-receptor like polypeptide and an adjuvant. It may be useful to conjugate a CD20/IgE-receptor like polypeptide to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet heocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals are bled and the serum is assayed for anti-CD20/IgE-receptor like polypeptide antibody titer.

Monoclonal antibodies directed toward a CD20/IgE-receptor like polypeptide are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler et al., *Nature*, 256:495-497 (1975) and the human B-cell hybridoma method, Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). Also provided by the invention are hybridoma cell lines which produce monoclonal antibodies reactive with CD20/IgE-receptor like polypeptides.

Monoclonal antibodies of the invention may be modified for use as therapeutics. One embodiment is a "chimeric" antibody in which a portion of the heavy and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a

particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass.

- 5 Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, U.S. Patent No. 4,816,567; Morrison et al., *Proc. Natl. Acad. Sci.*, 81:6851-6855 (1985).

10 In another embodiment, a monoclonal antibody of the invention is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art. See U.S. Patent Nos. 5,585,089, and 5,693,762. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be  
15 performed, for example, using methods described in the art. (See U.S. patent nos. 5,585,089 and 5,693,762). Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be performed, for example, using methods  
20 known in the art. (Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science* 239:1534-1536 (1988)), by substituting at least a portion of a rodent complementarity-determining region (CDR) for the corresponding regions of a human antibody.

- 25 Also encompassed by the invention are human antibodies which bind CD20/IgE-receptor like polypeptides. Using transgenic animals (e.g., mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production such antibodies are produced by  
30 immunization with a CD20/IgE-receptor like antigen (i.e., having at least 6 contiguous amino acids), optionally conjugated to a carrier. See, for example, Jakobovits et al., *Proc. Natl. Acad. Sci.*, 90:2551-2555 (1993); Jakobovits et al., *Nature* 362:255-258 (1993); Bruggermann et al., *Year in*



*Immuno.*, 7:33 (1993). In one method, such transgenic animals are produced by incapacitating the endogenous loci encoding the heavy and light immunoglobulin chains therein, and inserting loci encoding human heavy and light chain proteins into the genome thereof. Partially modified animals, that is those having less than the full complement of modifications, are then cross-bred to obtain an animal having all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies with human variable regions, including human (rather than e.g., murine) amino acid sequences, including variable regions, including human regions which are immunospecific for these antigens. See PCT application nos. PCT/US96/05928 and PCT/US93/06926. Additional methods are described in U.S. Patent No. 5,545,807, PCT application nos. PCT/US91/245, PCT/GB89/01207, and in EP 546073B1 and EP 546073A1. Human antibodies may also be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

In an alternative embodiment, human antibodies can be produced from phage-display libraries (Hoogenboom et al., *J. Mol. Biol.* 227:381 (1991); Marks et al., *J. Mol. Biol.* 222:581 (1991). These processes mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Application no. PCT/US98/17364, which describes the isolation of high affinity and functional agonistic antibodies for MPL- and msk- receptors using such an approach.

Chimeric, CDR grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein. In

a preferred embodiment, the antibodies are produced in mammalian host cells, such as CHO cells. Monoclonal (e.g., human) antibodies may be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

The anti-CD20/IgE-receptor like antibodies of the invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc., 1987)) for the detection and quantitation of CD20/IgE-receptor like polypeptides. The antibodies will bind CD20/IgE-receptor like polypeptides with an affinity which is appropriate for the assay method being employed.

For diagnostic applications, in certain embodiments, anti-CD20/IgE-receptor like antibodies may be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase,  $\beta$ -galactosidase, or horseradish peroxidase (Bayer et al., *Meth. Enz.*, 184:138-163 (1990)).

Competitive binding assays rely on the ability of a labeled standard (e.g., a CD20/IgE-receptor like polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (an CD20/IgE-receptor like polypeptide) for binding with a limited amount of anti CD20/IgE-receptor like antibody. The amount of a CD20/IgE-receptor like polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of

standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three part complex. See, e.g., U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

The selective binding agents, including anti-CD20/IgE-receptor like antibodies, also are useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

Selective binding agents of the invention, including antibodies, may be used as therapeutics. These therapeutic agents are generally agonists or antagonists, in that they either enhance or reduce, respectively, at least one of the biological activities of a CD20/IgE-receptor like polypeptide.

In one embodiment, antagonist antibodies of the invention are antibodies or binding fragments thereof which are capable of specifically binding to a CD20/IgE-receptor like polypeptide and which are capable of inhibiting or eliminating the functional activity of a CD20/IgE-receptor like polypeptide *in vivo* or *in vitro*. In preferred embodiments, the selective binding agent, e.g., an antagonist antibody, will inhibit the functional activity of a CD20/IgE-receptor like polypeptide by at least about 50%, and preferably by at least about 80%. In another embodiment, the selective binding agent may be an antibody that is capable of interacting with a CD20/IgE-receptor like binding partner (a ligand or receptor) thereby inhibiting or eliminating CD20/IgE-receptor like activity *in vitro* or *in vivo*. Selective binding agents, including agonist and antagonist anti-CD20/IgE-receptor like antibodies, are identified by screening assays which are well known in the art.

The invention also relates to a kit comprising CD20/IgE-receptor like selective binding agents (such as antibodies) and other reagents useful for detecting CD20/IgE-receptor like polypeptide levels in biological samples. Such reagents may include, a detectable label, blocking serum, positive and negative control samples, and detection reagents.

CD20/IgE-receptor like polypeptides can be used to clone CD20/IgE-receptor like ligand(s) using an "expression cloning" strategy. Radiolabeled (125-Iodine) CD20/IgE-receptor like polypeptide or "affinity/activity-tagged" CD20/IgE-receptor like polypeptide (such as an Fc fusion or an alkaline phosphatase fusion) can be used in binding assays to identify a cell type or cell line or tissue that expresses CD20/IgE-receptor like ligand(s). RNA isolated from such cells or tissues can then be converted to cDNA, cloned into a mammalian expression vector, and transfected into mammalian cells (for example, COS, or 293) to create an expression library.

Radiolabeled or tagged CD20/IgE-receptor like polypeptide can then be used as an affinity reagent to identify and isolate the subset of cells in this library expressing CD20/IgE-receptor like ligand(s). DNA is then isolated from these  
5 cells and transfected into mammalian cells to create a secondary expression library in which the fraction of cells expressing CD20/IgE-receptor like ligand(s) would be many-fold higher than in the original library. This enrichment process can be repeated iteratively until a single recombinant clone  
10 containing a CD20/IgE-receptor like ligand is isolated. Isolation of CD20/IgE-receptor like ligand(s) is useful for identifying or developing novel agonists and antagonists of the CD20/IgE-receptor like signaling pathway. Such agonists and antagonists include CD20/IgE-receptor like ligand(s),  
15 anti-CD20/IgE-receptor like ligand antibodies, small molecules, or antisense oligonucleotides.

#### Assaying for Other Modulators of CD20/IgE-Receptor Like Polypeptide Activity

20 In some situations, it may be desirable to identify molecules that are modulators, *i.e.*, agonists or antagonists, of the activity of CD20/IgE-receptor like polypeptide. Natural or synthetic molecules that modulate CD20/IgE-receptor like polypeptide may be identified using one or more screening  
25 assays, such as those described herein. Such molecules may be administered either in an *ex vivo* manner, or in an *in vivo* manner by injection, or by oral delivery, implantation device, or the like.

"Test molecule(s)" refers to the molecule(s) that is/are  
30 under evaluation for the ability to modulate (*i.e.*, increase or decrease) the activity of a CD20/IgE-receptor like polypeptide. Most commonly, a test molecule will interact directly with a CD20/IgE-receptor like polypeptide. However, it is also contemplated that a test molecule may also modulate

CD20/IgE-receptor like polypeptide activity indirectly, such as by affecting CD20/IgE-receptor like gene expression, or by binding to a CD20/IgE-receptor like binding partner (e.g., receptor or ligand). In one embodiment, a test molecule will  
5 bind to a CD20/IgE-receptor like polypeptide with an affinity constant of at least about  $10^{-6}$  M, preferably about  $10^{-8}$  M, more preferably about  $10^{-9}$  M, and even more preferably about  $10^{-10}$  M.

Methods for identifying compounds which interact with  
10 CD20/IgE-receptor like polypeptides are encompassed by the present invention. In certain embodiments, a CD20/IgE-receptor like polypeptide is incubated with a test molecule under conditions which permit the interaction of the test molecule with a CD20/IgE-receptor like polypeptide, and the  
15 extent of the interaction can be measured. The test molecule(s) can be screened in a substantially purified form or in a crude mixture.

In certain embodiments, a CD20/IgE-receptor like polypeptide agonist or antagonist may be a protein, peptide, carbohydrate, lipid, or small molecular weight molecule which  
20 interacts with CD20/IgE-receptor like polypeptide, or ligand thereof, to regulate its activity. Molecules which regulate CD20/IgE-receptor like polypeptide expression include nucleic acids which are complementary to nucleic acids encoding a  
25 CD20/IgE-receptor like polypeptide, or are complementary to nucleic acids sequences which direct or control the expression of CD20/IgE-receptor like polypeptide, and which act as anti-sense regulators of expression.

Once a set of test molecules has been identified as  
30 interacting with a CD20/IgE-receptor like polypeptide, the molecules may be further evaluated for their ability to increase or decrease CD20/IgE-receptor like polypeptide activity. The measurement of the interaction of test

molecules with CD20/IgE-receptor like polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test molecules are incubated with a  
5 CD20/IgE-receptor like polypeptide for a specified period of time, and CD20/IgE-receptor like polypeptide activity is determined by one or more assays for measuring biological activity.

The interaction of test molecules with CD20/IgE-receptor  
10 like polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay. Alternatively, modified forms of CD20/IgE-receptor like polypeptides containing epitope tags as described herein may be used in immunoassays.

15 In the event that CD20/IgE-receptor like polypeptides display biological activity through an interaction with a binding partner (e.g., a receptor or a ligand), a variety of *in vitro* assays may be used to measure the binding of a CD20/IgE-receptor like polypeptide to the corresponding  
20 binding partner (such as a selective binding agent, receptor, or ligand). These assays may be used to screen test molecules for their ability to increase or decrease the rate and/or the extent of binding of a CD20/IgE-receptor like polypeptide to its binding partner. In one assay, a CD20/IgE-receptor like  
25 polypeptide is immobilized in the wells of a microtiter plate. Radiolabeled CD20/IgE-receptor like binding partner (for example, iodinated CD20/IgE-receptor like binding partner) and the test molecule(s) can then be added either one at a time (in either order) or simultaneously to the wells. After  
30 incubation, the wells can be washed and counted, using a scintillation counter, for radioactivity to determine the extent to which the binding partner bound to CD20/IgE-receptor like polypeptide. Typically, the molecules will be tested over a range of concentrations, and a series of control wells

lacking one or more elements of the test assays can be used for accuracy in the evaluation of the results. An alternative to this method involves reversing the "positions" of the proteins, i.e., immobilizing CD20/IgE-receptor like binding partner to the microtiter plate wells, incubating with the test molecule and radiolabeled CD20/IgE-receptor like polypeptide, and determining the extent of CD20/IgE-receptor like polypeptide binding. See, for example, chapter 18, *Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, New York, NY (1995).

As an alternative to radiolabelling, a CD20/IgE-receptor like polypeptide or its binding partner may be conjugated to biotin and the presence of biotinylated protein can then be detected using streptavidin linked to an enzyme, such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), that can be detected colorometrically, or by fluorescent tagging of streptavidin. An antibody directed to a CD20/IgE-receptor like polypeptide or to a CD20/IgE-receptor like binding partner and conjugated to biotin may also be used and can be detected after incubation with enzyme-linked streptavidin linked to AP or HRP.

An CD20/IgE-receptor like polypeptide or a CD20/IgE-receptor like binding partner can also be immobilized by attachment to agarose beads, acrylic beads or other types of such inert solid phase substrates. The substrate-protein complex can be placed in a solution containing the complementary protein and the test compound. After incubation, the beads can be precipitated by centrifugation, and the amount of binding between a CD20/IgE-receptor like polypeptide and its binding partner can be assessed using the methods described herein. Alternatively, the substrate-protein complex can be immobilized in a column, and the test molecule and complementary protein are passed through the column. The formation of a complex between a CD20/IgE-



receptor like polypeptide and its binding partner can then be assessed using any of the techniques set forth herein, i.e., radiolabelling, antibody binding, or the like.

Another *in vitro* assay that is useful for identifying a  
5 test molecule which increases or decreases the formation of a  
complex between a CD20/IgE-receptor polypeptide and a  
CD20/IgE-receptor like binding partner is a surface plasmon  
resonance detector system such as the BIAcore assay system  
(Pharmacia, Piscataway, NJ). The BIAcore system may be  
10 carried out using the manufacturer's protocol. This assay  
essentially involves the covalent binding of either CD20/IgE-  
receptor like polypeptide or a CD20/IgE-receptor like binding  
partner to a dextran-coated sensor chip which is located in a  
detector. The test compound and the other complementary  
15 protein can then be injected, either simultaneously or  
sequentially, into the chamber containing the sensor chip.  
The amount of complementary protein that binds can be assessed  
based on the change in molecular mass which is physically  
associated with the dextran-coated side of the sensor chip;  
20 the change in molecular mass can be measured by the detector  
system.

In some cases, it may be desirable to evaluate two or  
more test compounds together for their ability to increase or  
decrease the formation of a complex between a CD20/IgE-  
25 receptor like polypeptide and a CD20/IgE-receptor like binding  
partner. In these cases, the assays set forth herein can be  
readily modified by adding such additional test compound(s)  
either simultaneous with, or subsequent to, the first test  
compound. The remainder of the steps in the assay are as set  
30 forth herein.

*In vitro* assays such as those described herein may be  
used advantageously to screen large numbers of compounds for  
effects on complex formation by CD20/IgE-receptor like

polypeptide and CD20/IgE-receptor like binding partner. The assays may be automated to screen compounds generated in phage display, synthetic peptide, and chemical synthesis libraries.

Compounds which increase or decrease the formation of a complex between a CD20/IgE-receptor like polypeptide and a CD20/IgE-receptor like binding partner may also be screened in cell culture using cells and cell lines expressing either CD20/IgE-receptor like polypeptide or CD20/IgE-receptor like binding partner. Cells and cell lines may be obtained from any mammal, but preferably will be from human or other primate, canine, or rodent sources. The binding of a CD20/IgE-receptor like polypeptide to cells expressing CD20/IgE-receptor like binding partner at the surface is evaluated in the presence or absence of test molecules, and the extent of binding may be determined by, for example, flow cytometry using a biotinylated antibody to a CD20/IgE-receptor like binding partner. Cell culture assays can be used advantageously to further evaluate compounds that score positive in protein binding assays described herein.

Cell cultures can also be used to screen the impact of a drug candidate. For example, drug candidates may decrease or increase the expression of the CD20/IgE-receptor like gene. In certain embodiments, the amount of CD20/IgE-receptor like polypeptide that is produced may be measured after exposure of the cell culture to the drug candidate. In certain embodiments, one may detect the actual impact of the drug candidate on the cell culture. For example, the overexpression of a particular gene may have a particular impact on the cell culture. In such cases, one may test a drug candidate's ability to increase or decrease the expression of the gene or its ability to prevent or inhibit a particular impact on the cell culture. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated

with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product in a cell culture.

A yeast two hybrid system (Chien et al., *Proc. Natl. Acad. Sci. USA*, 88:9578-9583 (1991)) can be used to identify novel polypeptides that bind to, or interact with, CD20/IgE-receptor like polypeptides. As an example, hybrid constructs comprising DNA encoding a cytoplasmic domain of a CD20/IgE-receptor like polypeptide fused to a yeast GAL4-DNA binding domain may be used as a two-hybrid bait plasmid. Positive clones emerging from the screening may be characterized further to identify interacting proteins.

#### Internalizing Proteins

The tat protein sequence (from HIV) can be used to internalize proteins into a cell. See e.g., Falwell et al., *Proc. Natl. Acad. Sci.*, 91:664-668 (1994). For example, an 11 amino acid sequence (YGRKKRRQRRR; SEQ ID NO: 24) of the HIV tat protein (termed the "protein transduction domain", or TAT PDT) has been described as mediating delivery across the cytoplasmic membrane and the nuclear membrane of a cell. See Schwarze et al., *Science*, 285:1569-1572 (1999); and Nagahara et al., *Nature Medicine*, 4:1449-1452 (1998). In these procedures, FITC-constructs (FITC-GGGGYGRKKRRQRRR; SEQ ID NO: 25) are prepared which bind to cells as observed by fluorescence-activated cell sorting (FACS) analysis, and these constructs penetrate tissues after i.p. administration. Next, tat-bgal fusion proteins are constructed. Cells treated with this construct demonstrated  $\beta$ -gal activity. Following injection, a number of tissues, including liver, kidney, lung, heart, and brain tissue have been found to demonstrate expression using these procedures. It is believed that these constructions underwent some degree of unfolding in order to

enter the cell; as such, refolding may be required after entering the cell.

It will thus be appreciated that the tat protein sequence may be used to internalize a desired protein or polypeptide into a cell. For example, using the tat protein sequence, a CD20/IgE-receptor like antagonist (such as an anti-CD20/IgE-receptor like selective binding agent, small molecule, soluble receptor, or antisense oligonucleotide) can be administered intracellularly to inhibit the activity of a CD20/IgE-receptor like molecule. As used herein, the term "CD20/IgE-receptor like molecule" refers to both CD20/IgE-receptor like nucleic acid molecules and CD20/IgE-receptor like polypeptides as defined herein. Where desired, the CD20/IgE-receptor like protein itself may also be internally administered to a cell using these procedures. See also, Strauss, E., "Introducing Proteins Into the Body's Cells", *Science*, 285:1466-1467 (1999).

#### **Cell Source Identification Using CD20/IgE-Receptor Like Polypeptides**

In accordance with certain embodiments of the invention, it may be useful to be able to determine the source of a certain cell type associated with a CD20/IgE-receptor like polypeptide. For example, it may be useful to determine the origin of a disease or pathological condition as an aid in selecting an appropriate therapy.

#### **Therapeutic Uses**

A non-exclusive list of acute and chronic diseases which can be treated, diagnosed, ameliorated, or prevented with the CD20/IgE-receptor like nucleic acids, polypeptides, and agonists and antagonists of the invention include:

- Cancer, including but not limited to: lung cancer, brain cancer, breast cancer, cancers of the hematopoietic system, prostate cancer, ovarian cancer, and testicular cancer. Other cancers are also encompassed within the scope of the invention.
- Diseases involving abnormal cell proliferation, including, but not limited to, arteriosclerosis and vascular restenosis. Other diseases influenced by the inappropriate proliferation of cells are also encompassed within the scope of the invention.
- Pathologies resulting from an inappropriate response to allergens. Examples of such diseases include, but are not limited to, allergies, asthma, dermatitis, and anaphylactic shock. Other diseases influenced by the dysfunction of allergic responses are encompassed within the scope of the invention.
- Diseases and conditions relating to dysfunction of the immune system, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, inflammatory arthritis, osteoarthritis, inflammatory joint disease, autoimmune disease, multiple sclerosis, lupus, diabetes, inflammatory bowel disease, transplant rejection, and graft vs. host disease. Other diseases influenced by the dysfunction of the immune system are encompassed within the scope of the invention.
- Reproductive diseases and disorders, including, but not limited to, infertility, miscarriage, preterm labor and delivery, and endometriosis. Other diseases of the reproductive system are encompassed within the scope of the invention.

Other diseases associated with undesirable levels of the present CD20/IgE-receptor like polypeptides are encompassed

within the scope of the invention. Undesirable levels include excessive levels and/or sub-normal levels of these polypeptides.

#### CD20/IgE-receptor like Compositions and Administration

5           Therapeutic compositions are within the scope of the present invention. Such CD20/IGE-receptor like pharmaceutical compositions may comprise a therapeutically effective amount of a CD20/IgE-receptor like polypeptide or a CD20/IgE-receptor like nucleic acid molecule in admixture with a  
10           pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. Pharmaceutical compositions may comprise a therapeutically effective amount of one or more CD20/IgE-receptor like selective binding agents in admixture with a  
15           pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

          Acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed.

20           The pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.  
25           Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates,  
30           phosphates, other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents

(such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrans), proteins (such as serum albumin, gelatin or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide), solvents (such as glycerin, propylene glycol or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal), stability enhancing agents (sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides (preferably sodium or potassium chloride), mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants. See *Remington's Pharmaceutical Sciences*, 18<sup>th</sup> Ed., A.R. Gennaro, ed., Mack Publishing Company (1990).

The optimal pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. See for example, *Remington's Pharmaceutical Sciences*, *supra*. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the CD20/IgE-receptor like molecule.

The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier may be water for injection, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral

administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may  
5 further include sorbitol or a suitable substitute therefor. In one embodiment of the present invention, CD20/IgE-receptor like polypeptide compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (*Remington's*  
10 *Pharmaceutical Sciences, supra*) in the form of a lyophilized cake or an aqueous solution. Further, the CD20/IgE-receptor like polypeptide product may be formulated as a lyophilizate using appropriate excipients such as sucrose.

The CD20/IgE-receptor like pharmaceutical compositions  
15 can be selected for parenteral delivery. Alternatively, the compositions may be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

20 The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.

25 When parenteral administration is contemplated, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the desired CD20/IgE-receptor like molecule in a pharmaceutically acceptable vehicle. A  
30 particularly suitable vehicle for parenteral injection is sterile distilled water in which a CD20/IgE-receptor like molecule is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as  
35 injectable microspheres, bio-erodible particles, polymeric



compounds (polylactic acid, polyglycolic acid), or beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered as a depot injection. Hyaluronic acid may also be used, and this may  
5 have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

In one embodiment, a pharmaceutical composition may be  
10 formulated for inhalation. For example, a CD20/IgE-receptor like molecule may be formulated as a dry powder for inhalation. CD20/IgE-receptor like polypeptide or CD20/IgE-receptor like nucleic acid molecule inhalation solutions may also be formulated with a propellant for aerosol delivery. In  
15 yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT application no. PCT/US94/001875, which describes pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations may be  
20 administered orally. In one embodiment of the present invention, CD20/IgE-receptor like molecules which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a  
25 capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the CD20/IgE-receptor like molecule. Diluents,  
30 flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

Another pharmaceutical composition may involve an effective quantity of CD20/IgE-receptor like molecules in a

mixture with non-toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are not  
5 limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

10 Additional CD20/IgE-receptor like pharmaceutical compositions will be evident to those skilled in the art, including formulations involving CD20/IgE-receptor like polypeptides in sustained- or controlled-delivery  
15 formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT/US93/00829 which describes controlled release of porous polymeric microparticles for the delivery of  
20 pharmaceutical compositions. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP  
25 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., *Biopolymers*, 22:547-556 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer et al., *J. Biomed. Mater. Res.*, 15:167-277 (1981) and Langer, *Chem. Tech.*, 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *supra*) or  
30 poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also may include liposomes, which can be prepared by any of several methods known in the art. See e.g., Epstein et al., *Proc. Natl. Acad. Sci. USA*, 82:3688-3692 (1985); EP 36,676; EP 88,046; EP 143,949.

The CD20/IgE-receptor like pharmaceutical composition to be used for *in vivo* administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, 5 sterilization using these methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a 10 sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, 15 gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

In a specific embodiment, the present invention is 20 directed to kits for producing a single-dose administration unit. The kits may each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled 25 syringes (e.g., liquid syringes and lyosyringes).

An effective amount of a CD20/IgE-receptor like pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the 30 appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the CD20/IgE-receptor like molecule is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and

general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range from about 0.1 µg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 µg/kg up to about 100 mg/kg; or 1 µg/kg up to about 100 mg/kg; or 5 µg/kg up to about 100 mg/kg.

The frequency of dosing will depend upon the pharmacokinetic parameters of the CD20/IgE-receptor like molecule in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.

The route of administration of the pharmaceutical composition is in accord with known methods, e.g. oral, injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, or intralesional routes, or by sustained release systems or implantation device. Where desired, the compositions may be administered by bolus injection or continuously by infusion, or by implantation device.

Alternatively or additionally, the composition may be administered locally via implantation of a membrane, sponge, or other appropriate material on to which the desired molecule

has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed release bolus, or continuous  
5 administration.

In some cases, it may be desirable to use CD20/IgE-receptor like pharmaceutical compositions in an ex vivo manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to CD20/IgE-  
10 receptor like pharmaceutical compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In other cases, a CD20/IgE-receptor like polypeptide can be delivered by implanting certain cells that have been  
15 genetically engineered, using methods such as those described herein, to express and secrete the polypeptide. Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be immortalized. In order to decrease the chance of an  
20 immunological response, the cells may be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the  
25 cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

Additional embodiments of the present invention relate to cells and methods (e.g., homologous recombination and/or other recombinant production methods) for both the in vitro  
30 production of therapeutic polypeptides and for the production and delivery of therapeutic polypeptides by gene therapy or cell therapy. Homologous and other recombination methods may be used to modify a cell that contains a normally transcriptionally silent CD20/IgE-receptor like gene, or an

under expressed gene, and thereby produce a cell which expresses therapeutically efficacious amounts of CD20/IgE-receptor like polypeptides.

Homologous recombination is a technique originally  
5 developed for targeting genes to induce or correct mutations in transcriptionally active genes (Kucherlapati, *Prog. in Nucl. Acid Res. & Mol. Biol.*, 36:301, 1989). The basic technique was developed as a method for introducing specific mutations into specific regions of the mammalian genome  
10 (Thomas et al., *Cell*, 44:419-428, 1986; Thomas and Capecchi, *Cell*, 51:503-512, 1987; Doetschman et al., *Proc. Natl. Acad. Sci.*, 85:8583-8587, 1988) or to correct specific mutations within defective genes (Doetschman et al., *Nature*, 330:576-578, 1987). Exemplary homologous recombination techniques are  
15 described in U.S. Patent No. 5,272,071 (EP 9193051, EP Publication No. 505500; PCT/US90/07642, International Publication No. WO 91/09955).

Through homologous recombination, the DNA sequence to be inserted into the genome can be directed to a specific region  
20 of the gene of interest by attaching it to targeting DNA. The targeting DNA is a nucleotide sequence that is complementary (homologous) to a region of the genomic DNA. Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during  
25 the DNA replication process. It is a general property of DNA that has been inserted into a cell to hybridize, and therefore, recombine with other pieces of endogenous DNA through shared homologous regions. If this complementary strand is attached to an oligonucleotide that contains a  
30 mutation or a different sequence or an additional nucleotide, it too is incorporated into the newly synthesized strand as a result of the recombination. As a result of the proofreading function, it is possible for the new sequence of DNA to serve

as the template. Thus, the transferred DNA is incorporated into the genome.

Attached to these pieces of targeting DNA are regions of DNA which may interact with or control the expression of a CD20/IgE-receptor like polypeptide, e.g., flanking sequences. For example, a promoter/enhancer element, a suppresser, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired CD20/IgE-receptor like polypeptide. The control element controls a portion of the DNA present in the host cell genome. Thus, the expression of the desired CD20/IgE-receptor like polypeptide may be achieved not by transfection of DNA that encodes the CD20/IgE-receptor like gene itself, but rather by the use of targeting DNA (containing regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the endogenous gene sequence with recognizable signals for transcription of a CD20/IgE-receptor like polypeptide.

In an exemplary method, the expression of a desired targeted gene in a cell (i.e., a desired endogenous cellular gene) is altered via homologous recombination into the cellular genome at a preselected site, by the introduction of DNA which includes at least a regulatory sequence, an exon and a splice donor site. These components are introduced into the chromosomal (genomic) DNA in such a manner that this, in effect, results in the production of a new transcription unit (in which the regulatory sequence, the exon and the splice donor site present in the DNA construct are operatively linked to the endogenous gene). As a result of the introduction of these components into the chromosomal DNA, the expression of the desired endogenous gene is altered.

Altered gene expression, as described herein, encompasses activating (or causing to be expressed) a gene which is normally silent (unexpressed) in the cell as obtained, as well as increasing the expression of a gene which is not expressed at physiologically significant levels in the cell as obtained. The embodiments further encompass changing the pattern of regulation or induction such that it is different from the pattern of regulation or induction that occurs in the cell as obtained, and reducing (including eliminating) the expression of a gene which is expressed in the cell as obtained.

One method by which homologous recombination can be used to increase, or cause, CD20/IgE-receptor like polypeptide production from a cell's endogenous CD20/IgE-receptor like gene involves first using homologous recombination to place a recombination sequence from a site-specific recombination system (e.g., Cre/loxP, FLP/FRT) (Sauer, *Current Opinion In Biotechnology*, 5:521-527, 1994; Sauer, *Methods In Enzymology*, 225:890-900, 1993) upstream (that is, 5' to) of the cell's endogenous genomic CD20/IgE-receptor like polypeptide coding region. A plasmid containing a recombination site homologous to the site that was placed just upstream of the genomic CD20/IgE-receptor like polypeptide coding region is introduced into the modified cell line along with the appropriate recombinase enzyme. This recombinase causes the plasmid to integrate, via the plasmid's recombination site, into the recombination site located just upstream of the genomic CD20/IgE-receptor like polypeptide coding region in the cell line (Baubonis and Sauer, *Nucleic Acids Res.*, 21:2025-2029, 1993; O'Gorman et al., *Science*, 251:1351-1355, 1991). Any flanking sequences known to increase transcription (e.g., enhancer/promoter, intron, translational enhancer), if properly positioned in this plasmid, would integrate in such a manner as to create a new or modified transcriptional unit resulting in *de novo* or increased CD20/IgE-receptor like



polypeptide production from the cell's endogenous CD20/IgE-receptor like gene.

5 A further method to use the cell line in which the site specific recombination sequence had been placed just upstream of the cell's endogenous genomic CD20/IgE-receptor like polypeptide coding region is to use homologous recombination to introduce a second recombination site elsewhere in the cell line's genome. The appropriate recombinase enzyme is then introduced into the two-recombination-site cell line, causing  
10 a recombination event (deletion, inversion, translocation) (Sauer, *Current Opinion In Biotechnology, supra*, 1994; Sauer, *Methods In Enzymology, supra*, 1993) that would create a new or modified transcriptional unit resulting in *de novo* or increased CD20/IgE-receptor like polypeptide production from  
15 the cell's endogenous CD20/IgE-receptor like gene.

An additional approach for increasing, or causing, the expression of CD20/IgE-receptor like polypeptide from a cell's endogenous CD20/IgE-receptor like gene involves increasing, or causing, the expression of a gene or genes (e.g.,  
20 transcription factors) and/or decreasing the expression of a gene or genes (e.g., transcriptional repressors) in a manner which results in *de novo* or increased CD20/IgE-receptor like polypeptide production from the cell's endogenous CD20/IgE-receptor like gene. This method includes the introduction of  
25 a non-naturally occurring polypeptide (e.g., a polypeptide comprising a site specific DNA binding domain fused to a transcriptional factor domain) into the cell such that *de novo* or increased CD20/IgE-receptor like polypeptide production from the cell's endogenous CD20/IgE-receptor like gene  
30 results.

The present invention further relates to DNA constructs useful in the method of altering expression of a target gene. In certain embodiments, the exemplary DNA constructs comprise:

(a) one or more targeting sequences; (b) a regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site. The targeting sequence in the DNA construct directs the integration of elements (a)-(d) into a target gene in a cell  
5 such that the elements (b)-(d) are operatively linked to sequences of the endogenous target gene. In another embodiment, the DNA constructs comprise: (a) one or more targeting sequences, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-  
10 acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that the elements of (b)-(f) are operatively linked to the endogenous gene. The targeting sequence is homologous to the preselected site in the cellular chromosomal DNA with which homologous  
15 recombination is to occur. In the construct, the exon is generally 3' of the regulatory sequence and the splice-donor site is 3' of the exon.

If the sequence of a particular gene is known, such as the nucleic acid sequence of CD20/IgE-receptor like  
20 polypeptide presented herein, a piece of DNA that is complementary to a selected region of the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece serves as a  
25 targeting sequence(s) upon insertion into the cell and will hybridize to its homologous region within the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence attached thereto, will act as an Okazaki fragment and will be incorporated into the newly  
30 synthesized daughter strand of DNA. The present invention, therefore, includes nucleotides encoding a CD20/IgE-receptor like polypeptide, which nucleotides may be used as targeting sequences.

CD20/IgE-receptor like polypeptide cell therapy, e.g., the implantation of cells producing CD20/IgE-receptor like polypeptides, is also contemplated. This embodiment involves implanting cells capable of synthesizing and secreting a  
5 biologically active form of CD20/IgE-receptor like polypeptide. Such CD20/IgE-receptor like polypeptide-producing cells can be cells that are natural producers of CD20/IgE-receptor like polypeptides or may be recombinant cells whose ability to produce CD20/IgE-receptor like  
10 polypeptides has been augmented by transformation with a gene encoding the desired CD20/IgE-receptor like polypeptide or with a gene augmenting the expression of CD20/IgE-receptor like polypeptide. Such a modification may be accomplished by means of a vector suitable for delivering the gene as well as  
15 promoting its expression and secretion. In order to minimize a potential immunological reaction in patients being administered a CD20/IgE-receptor like polypeptide, as may occur with the administration of a polypeptide of a foreign species, it is preferred that the natural cells producing  
20 CD20/IgE-receptor like polypeptide be of human origin and produce human CD20/IgE-receptor like polypeptide. Likewise, it is preferred that the recombinant cells producing CD20/IgE-receptor like polypeptide be transformed with an expression vector containing a gene encoding a human CD20/IgE-receptor  
25 like polypeptide.

Implanted cells may be encapsulated to avoid the infiltration of surrounding tissue. Human or non-human animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow the  
30 release of CD20/IgE-receptor like polypeptide, but that prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue. Alternatively, the patient's own cells, transformed to produce CD20/IgE-receptor like polypeptides ex vivo, may be

implanted directly into the patient without such encapsulation.

Techniques for the encapsulation of living cells are known in the art, and the preparation of the encapsulated cells and their implantation in patients may be routinely accomplished. For example, Baetge et al. (WO95/05452; PCT/US94/09299) describe membrane capsules containing genetically engineered cells for the effective delivery of biologically active molecules. The capsules are biocompatible and are easily retrievable. The capsules encapsulate cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation *in vivo* upon implantation into a mammalian host. The devices provide for the delivery of the molecules from living cells to specific sites within a recipient. In addition, see U.S. Patent Nos. 4,892,538, 5,011,472, and 5,106,627. A system for encapsulating living cells is described in PCT Application no. PCT/US91/00157 of Aebischer et al. See also, PCT Application no. PCT/US91/00155 of Aebischer et al., Winn et al., *Exper. Neurol.*, 113:322-329 (1991), Aebischer et al., *Exper. Neurol.*, 111:269-275 (1991); and Tresco et al., *ASAIO*, 38:17-23 (1992).

*In vivo* and *in vitro* gene therapy delivery of CD20/IgE-receptor like polypeptides is also envisioned. One example of a gene therapy technique is to use the CD20/IgE-receptor like gene (either genomic DNA, cDNA, and/or synthetic DNA) encoding a CD20/IgE-receptor like polypeptide which may be operably linked to a constitutive or inducible promoter to form a "gene therapy DNA construct". The promoter may be homologous or heterologous to the endogenous CD20/IgE-receptor like gene, provided that it is active in the cell or tissue type into which the construct will be inserted. Other components of the gene therapy DNA construct may optionally include, DNA molecules designed for site-specific integration (e.g.,

endogenous sequences useful for homologous recombination), tissue-specific promoter, enhancer(s) or silencer(s), DNA molecules capable of providing a selective advantage over the parent cell, DNA molecules useful as labels to identify transformed cells, negative selection systems, cell specific binding agents (as, for example, for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as factors to enable vector manufacture.

10 A gene therapy DNA construct can then be introduced into cells (either *ex vivo* or *in vivo*) using viral or non-viral vectors. One means for introducing the gene therapy DNA construct is by means of viral vectors as described herein. Certain vectors, such as retroviral vectors, will deliver the DNA construct to the chromosomal DNA of the cells, and the gene can integrate into the chromosomal DNA. Other vectors will function as episomes, and the gene therapy DNA construct will remain in the cytoplasm.

20 In yet other embodiments, regulatory elements can be included for the controlled expression of the CD20/IgE-receptor like gene in the target cell. Such elements are turned on in response to an appropriate effector. In this way, a therapeutic polypeptide can be expressed when desired. One conventional control means involves the use of small molecule dimerizers or rapalogs (as described in WO9641865 (PCT/US96/099486); WO9731898 (PCT/US97/03137) and WO9731899 (PCT/US95/03157) used to dimerize chimeric proteins which contain a small molecule-binding domain and a domain capable of initiating biological process, such as a DNA-binding protein or transcriptional activation protein. The dimerization of the proteins can be used to initiate transcription of the transgene.

An alternative regulation technology uses a method of storing proteins expressed from the gene of interest inside the cell as an aggregate or cluster. The gene of interest is expressed as a fusion protein that includes a conditional  
5 aggregation domain which results in the retention of the aggregated protein in the endoplasmic reticulum. The stored proteins are stable and inactive inside the cell. The proteins can be released, however, by administering a drug (e.g., small molecule ligand) that removes the conditional  
10 aggregation domain and thereby specifically breaks apart the aggregates or clusters so that the proteins may be secreted from the cell. See, *Science* 287:816-817, and 826-830 (2000).

Other suitable control means or gene switches include, but are not limited to, the following systems. Mifepristone  
15 (RU486) is used as a progesterone antagonist. The binding of a modified progesterone receptor ligand-binding domain to the progesterone antagonist activates transcription by forming a dimer of two transcription factors which then pass into the nucleus to bind DNA. The ligand binding domain is modified to  
20 eliminate the ability of the receptor to bind to the natural ligand. The modified steroid hormone receptor system is further described in U.S. 5,364,791; WO9640911, and WO9710337.

Yet another control system uses ecdysone (a fruit fly steroid hormone) which binds to and activates an ecdysone  
25 receptor (cytoplasmic receptor). The receptor then translocates to the nucleus to bind a specific DNA response element (promoter from ecdysone-responsive gene). The ecdysone receptor includes a transactivation domain/DNA-binding domain/ligand-binding domain to initiate  
30 transcription. The ecdysone system is further described in U.S. 5,514,578; WO9738117; WO9637609; and WO9303162.

Another control means uses a positive tetracycline-controllable transactivator. This system involves a mutated

tet repressor protein DNA-binding domain (mutated tet R-4 amino acid changes which resulted in a reverse tetracycline-regulated transactivator protein, i.e., it binds to a tet operator in the presence of tetracycline) linked to a polypeptide which activates transcription. Such systems are described in U.S. Patent Nos. 5,464,758; 5,650,298 and 5,654,168.

Additional expression control systems and nucleic acid constructs are described in U.S. Patent Nos. 5,741,679 and 5,834,186, to Innovir Laboratories Inc.

In vivo gene therapy may be accomplished by introducing the gene encoding a CD20/IgE-receptor like polypeptide into cells via local injection of a CD20/IgE-receptor like nucleic acid molecule or by other appropriate viral or non-viral delivery vectors. Hefti, *Neurobiology*, 25:1418-1435 (1994). For example, a nucleic acid molecule encoding a CD20/IgE-receptor like polypeptide may be contained in an adeno-associated virus (AAV) vector for delivery to the targeted cells (e.g., Johnson, International Publication No. WO95/34670; International Application No. PCT/US95/07178). The recombinant AAV genome typically contains AAV inverted terminal repeats flanking a DNA sequence encoding a CD20/IgE-receptor like polypeptide operably linked to functional promoter and polyadenylation sequences.

Alternative suitable viral vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus, lentivirus, hepatitis virus, parvovirus, papovavirus, poxvirus, alphavirus, coronavirus, rhabdovirus, paramyxovirus, and papilloma virus vectors. U.S. Patent No. 5,672,344 describes an *in vivo* viral-mediated gene transfer system involving a recombinant neurotrophic HSV-1 vector. U.S. Patent No. 5,399,346 provides examples of a process for providing a patient with a therapeutic protein by the delivery

of human cells which have been treated *in vitro* to insert a DNA segment encoding a therapeutic protein. Additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 5,631,236  
5 involving adenoviral vectors; U.S. Patent No. 5,672,510 involving retroviral vectors; and U.S. 5,635,399 involving retroviral vectors expressing cytokines.

Nonviral delivery methods include, but are not limited to, liposome-mediated transfer, naked DNA delivery (direct  
10 injection), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation, and microparticle bombardment (e.g., gene gun). Gene therapy materials and methods may also include the use of inducible promoters, tissue-specific enhancer-promoters, DNA sequences  
15 designed for site-specific integration, DNA sequences capable of providing a selective advantage over the parent cell, labels to identify transformed cells, negative selection systems and expression control systems (safety measures), cell-specific binding agents (for cell targeting), cell-  
20 specific internalization factors, and transcription factors to enhance expression by a vector as well as methods of vector manufacture. Such additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 4,970,154 involving electroporation techniques;  
25 WO96/40958 involving nuclear ligands; U.S. Patent No. 5,679,559 describing a lipoprotein-containing system for gene delivery; U.S. Patent No. 5,676,954 involving liposome carriers; U.S. Patent No. 5,593,875 concerning methods for calcium phosphate transfection; and U.S. Patent No. 4,945,050  
30 wherein biologically active particles are propelled at cells at a speed whereby the particles penetrate the surface of the cells and become incorporated into the interior of the cells.

It is also contemplated that CD20/IgE-receptor like gene therapy or cell therapy can further include the delivery of



one or more additional polypeptide(s) in the same or a different cell(s). Such cells may be separately introduced into the patient, or the cells may be contained in a single implantable device, such as the encapsulating membrane described above, or the cells may be separately modified by means of viral vectors.

A means to increase endogenous CD20/IgE-receptor like polypeptide expression in a cell via gene therapy is to insert one or more enhancer elements into the CD20/IgE-receptor like polypeptide promoter, where the enhancer element(s) can serve to increase transcriptional activity of the CD20/IgE-receptor like gene. The enhancer element(s) used will be selected based on the tissue in which one desires to activate the gene(s); enhancer elements known to confer promoter activation in that tissue will be selected. For example, if a gene encoding a CD20/IgE-receptor like polypeptide is to be "turned on" in T-cells, the *lck* promoter enhancer element may be used. Here, the functional portion of the transcriptional element to be added may be inserted into a fragment of DNA containing the CD20/IgE-receptor like polypeptide promoter (and optionally, inserted into a vector and/or 5' and/or 3' flanking sequence(s), etc.) using standard cloning techniques. This construct, known as a "homologous recombination construct", can then be introduced into the desired cells either *ex vivo* or *in vivo*.

Gene therapy also can be used to decrease CD20/IgE-receptor like polypeptide expression by modifying the nucleotide sequence of the endogenous promoter(s). Such modification is typically accomplished via homologous recombination methods. For example, a DNA molecule containing all or a portion of the promoter of the CD20/IgE-receptor like gene(s) selected for inactivation can be engineered to remove and/or replace pieces of the promoter that regulate transcription. For example the TATA box and/or the binding site of a transcriptional activator of the promoter may be

deleted using standard molecular biology techniques; such deletion can inhibit promoter activity thereby repressing the transcription of the corresponding CD20/IgE-receptor like gene. The deletion of the TATA box or the transcription  
5 activator binding site in the promoter may be accomplished by generating a DNA construct comprising all or the relevant portion of the CD20/IgE-receptor like polypeptide promoter(s) (from the same or a related species as the CD20/IgE-receptor like gene(s) to be regulated) in which one or more of the TATA  
10 box and/or transcriptional activator binding site nucleotides are mutated via substitution, deletion and/or insertion of one or more nucleotides. As a result, the TATA box and/or activator binding site has decreased activity or is rendered completely inactive. The construct will typically contain at  
15 least about 500 bases of DNA that correspond to the native (endogenous) 5' and 3' DNA sequences adjacent to the promoter segment that has been modified. The construct may be introduced into the appropriate cells (either *ex vivo* or *in vivo*) either directly or via a viral vector as described  
20 herein. Typically, the integration of the construct into the genomic DNA of the cells will be via homologous recombination, where the 5' and 3' DNA sequences in the promoter construct can serve to help integrate the modified promoter region via hybridization to the endogenous chromosomal DNA.

#### **Additional Uses of CD20/IgE-receptor like Nucleic Acids and Polypeptides**

Nucleic acid molecules of the present invention (including those that do not themselves encode biologically  
30 active polypeptides) may be used to map the locations of the CD20/IgE-receptor like gene and related genes on chromosomes. Mapping may be done by techniques known in the art, such as PCR amplification and *in situ* hybridization.

CD20/IgE-receptor like nucleic acid molecules (including  
35 those that do not themselves encode biologically active

polypeptides), may be useful as hybridization probes in diagnostic assays to test, either qualitatively or quantitatively, for the presence of a CD20/IgE-receptor like DNA or corresponding RNA in mammalian tissue or bodily fluid samples.

The CD20/IgE-receptor like polypeptides may be used (simultaneously or sequentially) in combination with one or more cytokines, growth factors, antibiotics, anti-inflammatory, and/or chemotherapeutic agents as is appropriate for the indication being treated.

Other methods may also be employed where it is desirable to inhibit the activity of one or more CD20/IgE-receptor like polypeptides. Such inhibition may be effected by nucleic acid molecules which are complementary to and hybridize to expression control sequences (triple helix formation) or to CD20/IgE-receptor like mRNA. For example, antisense DNA or RNA molecules, which have a sequence that is complementary to at least a portion of the selected CD20/IgE-receptor like gene(s) can be introduced into the cell. Antisense probes may be designed by available techniques using the sequence of CD20/IgE-receptor like polypeptide disclosed herein. Typically, each such antisense molecule will be complementary to the start site (5' end) of each selected CD20/IgE-receptor like gene. When the antisense molecule then hybridizes to the corresponding CD20/IgE-receptor like mRNA, translation of this mRNA is prevented or reduced. Antisense inhibitors provide information relating to the decrease or absence of a CD20/IgE-receptor like polypeptide in a cell or organism.

Alternatively, gene therapy may be employed to create a dominant-negative inhibitor of one or more CD20/IgE-receptor like polypeptides. In this situation, the DNA encoding a mutant polypeptide of each selected CD20/IgE-receptor like polypeptide can be prepared and introduced into the cells of a patient using either viral or non-viral methods as described

herein. Each such mutant is typically designed to compete with endogenous polypeptide in its biological role.

In addition, a CD20/IgE-receptor like polypeptide, whether biologically active or not, may be used as an immunogen, that is, the polypeptide contains at least one epitope to which antibodies may be raised. Selective binding agents that bind to a CD20/IgE-receptor like polypeptide (as described herein) may be used for *in vivo* and *in vitro* diagnostic purposes, including, but not limited to, use in labeled form to detect the presence of CD20/IgE-receptor like polypeptide in a body fluid or cell sample. The antibodies may also be used to prevent, treat, or diagnose a number of diseases and disorders, including those recited herein. The antibodies may bind to a CD20/IgE-receptor like polypeptide so as to diminish or block at least one activity characteristic of a CD20/IgE-receptor like polypeptide, or may bind to a polypeptide to increase at least one activity characteristic of a CD20/IgE-receptor like polypeptide (including by increasing the pharmacokinetics of the CD20/IgE-receptor like polypeptide).

The following examples will serve to further typify the nature of the invention, but should not be construed as a limitation on the scope thereof which is defined solely by the appended claims.

#### EXAMPLE 1

##### Cloning of CD20/IgE-Receptor Like cDNA (AGP-69406-a1)

Agp-69406-a1 (CD20RP1) was identified based on homology to a mouse gene (agp-65220-a1) which was isolated at Amgen. Homology-based BLAST searches of the public databases identified a 428 nt DNA fragment (smbr7-00044-b9-a) which upon translation displayed homology to the human IgER/FC $\gamma$ RI. Based on this homology, the entire smbr7-00044-b9 insert was

sequenced. The smbr7 library was constructed as follows:  
total RNA was extracted from the crushed bone femur and tibia  
from osteoprotegerin (OPG) knockout mice using standard RNA  
extraction procedures and poly-A<sup>+</sup> RNA was selected from this  
5 total RNA using standard procedures known to those skilled in  
the art. Random primed or oligo(dT) primed cDNA was  
synthesized from this poly-A<sup>+</sup> RNA using the procedure in the  
manual of the Superscript Plasmid System for cDNA Synthesis  
and Plasmid Cloning kit (Gibco-BRL, Inc., Rockville, MD) or  
10 using other suitable procedures known to those skilled in the  
art. The resulting cDNA was digested with appropriate  
restriction enzymes to create sticky ends to assist in  
ligation to a cloning vector. This digested cDNA was ligated  
into the pSPORT 1 cloning vector, or another suitable cloning  
15 vector known to those skilled in the art, that had been pre-  
digested with appropriate restriction enzymes. The ligation  
products were transformed into *E. coli* using standard  
techniques known in the art, and transformants were selected  
on bacterial media plates containing either ampicillin,  
20 tetracycline, kanamycin or chloramphenicol, depending upon the  
specific cloning vector used. The cDNA library consisted of  
all, or a subset, of these transformants. Homology-based  
searches of Amgenesis and the public databases using the  
smbr7-00044-b9 sequence identified several related human DNA  
25 fragments from which it was possible to build the virtual  
contiguous sequence ahgil-030853-cya. Attempts to isolate the  
coding region based on this sequence yielded multiple bands,  
so 5' and 3' RACE were employed to isolate the actual coding  
region. For both RACE reactions, human skeletal muscle  
30 Marathon cDNA (Clontech, Palo Alto, CA) was used as template.  
For 5' RACE, the first round reaction used the primers 2277-69  
(5'-CAG CCC GTT CTG CAG GTA ATC TTC-3'SEQ ID NO: 5) and AP1  
(5'-CCA TCC TAA TAC GAC TCA CTA TAG GGC-3'SEQ ID NO:  
6, Clontech) with 0.2 ng of template DNA, 0.2 uM final each

primer, 0.2 mM final concentration of nucleotides, and 0.5 µl of Advantage cDNA polymerase mix (Clontech) in a reaction volume of 25 µl. After PCR, the first round reaction was diluted 1:50 and 5 µl were used in a final reaction volume of 50 µl. This reaction had a 0.2 mM final concentration of nucleotides, 0.2 uM final each primer and 1 µl of Advantage cDNA polymerase mix. The primers used for the second round reaction were 2277-70 (5'-ATG TGT CCA GGT TTC TCT CTT TGA G-3'; SEQ ID NO: 7) and AP2 (5'-ACT CAC TAT AGG GCT CGA GCG GC-3' SEQ ID NO: 8, Clontech). 3' RACE used the same reactions conditions with the different primer set 2277-72 (5'-TTA CTG CAG GAG CAG GCC TCT TC-3'; SEQ ID NO: 9) and AP1 for the first round, while the primer set 2277-73 (5'-CAG CAT GGT AGC CCT GAG GAC TG-3'; SEQ ID NO: 10) and the AP2 primer were used in the second round. PCR conditions for both first round reactions consisted of 94°C for 2 min, followed by 5 cycles (94°C for 10 sec, 72°C for 2 min), followed by 5 cycles (94°C for 10 sec, 70°C for 2 min), followed by an additional 25 cycles (94°C for 10 sec, 68°C for 2 min). The PCR conditions for both second round reactions were the same as the first round conditions except that in the second round, the last cycle condition was performed for 15 cycles instead of 25 cycles. After sequencing RACE products, it was possible to design primers to amplify the entire open reading frame (ORF). The primer set 2289-28 (5'-CAA CAC GTC GAC CCA CCA TGC TAT TAC AAT CCC AAA CCA TGG G-3'; SEQ ID NO: 11) and 2289-29 (5'-CAA CAA GCG GCC GCA GTT GCT TTT CCT TCC TCT GAG GC-3'; SEQ ID NO: 12) were used on human skeletal muscle marathon cDNA to amplify the entire ORF using the same PCR conditions as described for the first round of RACE above. The amplified PCR product was digested with the appropriate restriction enzymes and subcloned into the pSPORT plasmid (Life Sciences Technology).

EXAMPLE 2

Cloning of a CD20/IgE-receptor like cDNA (AGP-96614-a1)

5 Agp-96614-a1 (CD20RP2) was first identified based on  
homology to a contig generated by computer analysis starting  
with the 401nt mouse sequence (ymmn1-00775-h7-a) which was  
isolated at Amgen. The ymmn1 library was constructed as  
follows: total RNA was extracted and pooled from the multiple  
10 mouse tissues using standard RNA extraction procedures and  
poly-A<sup>+</sup> RNA was selected from this total RNA using standard  
procedures known to those skilled in the art. Random primed  
or oligo(dT) primed cDNA was synthesized from this poly-A<sup>+</sup> RNA  
using the procedure in the manual of the Superscript Plasmid  
15 System for cDNA Synthesis and Plasmid Cloning kit (Gibco-BRL,  
Inc., Rockville, MD) or using other suitable procedures known  
to those skilled in the art. The resulting cDNA was digested  
with appropriate restriction enzymes to create sticky ends to  
assist in ligation to a cloning vector. This digested cDNA  
20 was ligated into the pSPORT 1 cloning vector, or another  
suitable cloning vector known to those skilled in the art,  
that had been pre-digested with appropriate restriction  
enzymes. The ligation products were transformed into *E. coli*  
using standard techniques known in the art, and transformants  
25 were selected on bacterial media plates containing either  
ampicillin, tetracycline, kanamycin, or chloramphenicol,  
depending upon the specific cloning vector used. The cDNA  
library consisted of all, or a subset, of these transformants.  
Homology-based BLAST searches of the public databases  
30 identified a 691 nt DNA fragment (ahgi-098696-cya1) which upon  
translation displayed homology to the human IgER/FC<sub>γ</sub>RI.  
Although it appeared that this fragment contained the entire  
coding region, 5' and 3' RACE were employed to identify the  
actual correct ORF. For both RACE reactions, human testes  
35 Marathon cDNA (Clontech, Palo Alto, CA) was used as template.

For 5' RACE, the first round reaction used the primers 2277-19 (GGA AGA TAA CTC CAA AAG AAA AGG TC-3' SEQ ID NO: 13) and AP1 (see above) with 0.2 ng of template DNA, 0.2 uM final each primer, 0.2 mM final concentration of nucleotides, and 0.5 µl of Advantage cDNA polymerase mix (Clontech) in a reaction volume of 25 µl. After PCR, the first round reaction was diluted 1:50 and 5 µl were used in a final reaction volume of 50 µl. This reaction contained a 0.2 mM final concentration of nucleotides, 0.2 uM final each primer and 1 µl of Advantage cDNA polymerase mix. The primers used for the second round reaction were 2277-20 (5'-AAA CAG GAT CTG GAT AGT CCC TAA G-3' SEQ ID NO: 14) and AP2 (see above). 3' RACE used the same reactions conditions with the different primer set 2277-22 (5'-CCT CAC ATT TGG TTT CAT CCT AGA TC-3' SEQ ID NO: 15) and AP1 for the first round, while the primer set 2277-23 (5'-GTC AGT GTA AGG CTG TTA CTG TCC-3' SEQ ID NO: 16) and the AP2 primer were used in the second round. PCR conditions for both first round reactions consisted of 94°C for 2 min, followed by 5 cycles (94°C for 10 sec, 72°C for 2 min), followed by 5 cycles (94°C for 10 sec, 70°C for 2 min), followed by an additional 25 cycles (94°C for 10 sec, 68°C for 2 min). The PCR conditions for both second round reactions were the same as the first round conditions except that in the second round, the last cycle condition was performed for 15 cycles instead of 25 cycles. After sequencing RACE products, it was possible to design primers to amplify the entire ORF. The primer set 2289-26 (5'-CAA CAC GTC GAC CCA CCA TGG ATT CAA GCA CCG CAC ACA GT-3' SEQ ID NO: 17) and 2289-27 (5'-CAA CAA GCG GCC GCT TAA CAC ATC TTT ATT CTC ACA GTG CT-3' SEQ ID NO: 18) were used on human testes marathon cDNA to amplify the entire ORF using the same PCR conditions as described for the first round of RACE above. The amplified PCR product was digested with the appropriate restriction enzymes and subcloned into the pSPORT plasmid (Life Sciences Technology).



### EXAMPLE 3

#### Presence and Distribution of mRNA in Different Tissues

Northern blot analysis of the MTE blots (Clontech, CA) indicated that agp-69406-a1 was expressed predominantly in human adult and fetal spleen, adult, and fetal lung, placenta, and fetal liver. Northern blot analysis of RNA from cell lines also detected a ~3.5 kB transcript in THP-1 (acute monocytic leukemia). PCR analysis detected agp-69406-a1 in human brain, kidney, spleen, thymus, adult and fetal liver, muscle, testis, placenta, pancreas, ovary, prostate, peripheral blood leukocytes, and bone marrow.

Northern blot analysis of the MTE blots (Clontech, CA) indicated that agp-96614-a1 was expressed predominantly in human testis. PCR analysis detected agp-96614-a1 in human testes, pancreas, a colon adenocarcinoma cell line (CX-1), and an ovarian carcinoma cell line (GI-102). Method detail is included below.

#### RT PCR

To examine the expression of agp-69406-a1 and agp-96614-a1, RT PCR was performed using multi-tissue cDNA panels (MTC) as template and Advantage cDNA polymerase mix (Clontech). PCR used the primers 2323-64 (5'-AGC AGG CCT CTT CCT CCT TGC TGA-3' SEQ ID NO: 19), 2323-63 (5'-TGA ACT CCC AGG GTT GTT GGA GT-3' SEQ ID NO: 20) for agp- 69406-a1, and 2323-69 (5'-CTG GAG CCT TCCC TAA TTG CAG TGA-3' SEQ ID NO: 21), 2323-70 (5'-CAA TCA CAA TCC TCT GAG TGG CA-3' SEQ ID NO: 22) for agp-96614-a1 at final concentration of 0.4  $\mu$ M with ~1ng of template DNA, 0.2 mM final concentration of nucleotides, and 1  $\mu$ l of Advantage cDNA polymerase mix in a reaction volume of 50  $\mu$ l. The cycling conditions were 94°C for 30 sec, (94°C for 30 sec, 68°C for 2 min.) repeat 30 times, 68°C for 5 min.

## MTE array blot

### Probe preparation

The probe for agp-69406-a1 was prepared by PCR and gel purification two times. PCR product of 331 base pair in size was amplified using Pharmacia PCR beads with 2323-64 (5'-AGC AGG CCT CTT CCT CCT TGC TGA-3' SEQ ID No; 19), 2323-61 (5'-CCA AGA CCG TGA AGA ACT CT-3' SEQ ID NO: 23) at final concentration of 0.4 $\mu$ M and ~2ng of full length agp-69406 DNA as template. The cycling conditions were 94°C for 1 min., (94°C for 30 sec., 70°C for 1 min. 30 sec.) repeat 30 times, 72°C for 10 min. The probe for agp-96614-a1 was prepared same as above except 295 base pair PCR product was amplified using the primers 2323-69 (5'-CTG GAG CCT TCCC TAA TTG CAG TGA-3' SEQ ID NO: 21), 2323-70 (5'-CAA TCA CAA TCC TCT GAG TGG CA-3' SEQ ID NO: 22) and full length agp-96614 DNA as template.

### Hybridizations

Probes were labeled with [ $\alpha$ -<sup>32</sup>P] dCTP (10 mCi/ml Amersham Pharmacia Biotech Catalog #AA0005) using the rediprime<sup>TM</sup> II (Amersham Pharmacia Biotech Catalog #RPN-1633) and purified by Sephadex G-50 column (Boehringer Mannheim Catalog #1273965) followed by spinning at 2,500 rpm for 5 minutes. Multiple tissue expression arrays (Clontech Catalog #7775-1) which include cDNA from 76 human tissues of mRNA were prehybridized in 10 ml ExpressHyb (Clontech Catalog #S0910) that contained 1.5 mg of denatured sheared salmon testes DNA (Sigma D7656) for 2 hours with continuous agitation at 65°C. Probe was denatured in 250  $\mu$ l of 6xSSC containing 5 x 10<sup>6</sup> cpm labeled probe, 30  $\mu$ g of Cot-1 DNA, 150  $\mu$ g of denatured sheared salmon testes DNA in 250  $\mu$ l of 6x SSC, added to the prehybridization mixture and incubated for 18 hr at 65°C. Free probe was removed by washing in 2x SSC; 1% SDS for 20 minutes with continuous agitation at 65°C each five times. Two additional

20 minutes washes in solution 2 (0.1X SSC; 0.5% SDS) with continuous agitation at 55°C were performed. Hybridization was detected by exposure to x-ray film at -70°C with an intensifying screen.

5 Northern blot was generated using Northern MAX-Gly kit(Ambion) with 10µg of total RNA extracted from 19 human hematopoietic cell lines at Amgen. For hybridization the membrane was prehybridized in 10ml of Express hybridization solution (Clontech) with 100µg/ml of denatured salmon sperm  
10 DNA at 65°C for 3 hours. Then the probe (prepared in the same manner as used in MTE array blot) labeled with P<sup>32</sup> using readiprime kit (Amersham) was added at 1X10<sup>6</sup> cpm/ml and left at 65°C for 16 hours. The membrane was washed with 2XSSC, 0.05% SDS for 10 minutes, 4 times at 65°C, and 1XSSC, 0.1% SDS  
15 for 20 minutes, 2 times at 65°C. The membrane was then exposed to X-ray film overnight at -80°C.